CLUH controls astrin-1 expression to couple mitochondrial metabolism to cell cycle progression

Désirée Schatton^{1,2}, Giada Di Pietro^{1,2}, Karolina Szczepanowska^{2,3,#}, Matteo Veronese^{1,2}, Marie-Charlotte Marx^{1,2}, Kristina Braunöhler^{1,2}, Esther Barth^{1,2}, Stefan Müller², Patrick Giavalisco⁴, Thomas Langer^{2,4}, Aleksandra Trifunovic^{2,3,5} and Elena I. Rugarli^{1,2,5*}

¹Institute for Genetics, University of Cologne, Cologne 50931, Germany

²Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne 50931, Germany

³Institute for Mitochondrial Diseases and Ageing, University of Cologne, Cologne 50931, Germany

⁴Max Planck Institute for Biology of Ageing, Cologne 50931, Germany.

⁵Center for Molecular Medicine (CMMC), University of Cologne, Cologne 50931, Germany.

Present address: ReMedy International Research Agenda Unit, IMol Polish Academy of Sciences, Warsaw, Poland

*Correspondence: elena.rugarli@uni-koeln.de

Abstract

Proliferating cells undergo metabolic changes in synchrony with cell cycle progression and cell division. Mitochondria provide fuel, metabolites, and ATP during different phases of the cell cycle, however it is not completely understood how mitochondrial function and the cell cycle are coordinated. CLUH is a post-transcriptional regulator of mRNAs encoding mitochondrial proteins involved in oxidative phosphorylation and several metabolic pathways. Here, we show a role of CLUH in regulating the expression of astrin, which is involved in metaphase to anaphase progression, centrosome integrity, and mTORC1 inhibition. We find that CLUH binds both the *SPAG5* mRNA and its product astrin, and controls the synthesis and the stability of the full-length astrin-1 isoform. We show that CLUH interacts with astrin-1 specifically during interphase. Astrin-depleted cells show mislocalized CLUH at focal adhesions, mTORC1 hyperactivation and enhanced anabolism. On the other hand, cells lacking CLUH show decreased astrin levels and increased mTORC1 signaling, but cannot sustain anaplerotic and anabolic pathways. In absence of CLUH, cells fail to grow during G1, and progress faster through the cell cycle, indicating dysregulated matching of growth, metabolism and cell cycling. Our data reveal a role of CLUH in coupling growth signaling pathways and mitochondrial metabolism with cell cycle progression.

Introduction

Proliferating cells adjust their metabolism to each individual phase of the cell cycle (DeBerardinis et al, 2008; Buchakjian & Kornbluth, 2010; Lee & Finkel, 2013; Salazar-Roa & Malumbres, 2017). Before division cells must double their biomass and DNA content. This entails a prominent rewiring of metabolism to foster biosynthetic pathways allowing the synthesis of nucleic acids, proteins and lipids. During mitosis, an increase in ATP production supplies the energy needed for pulling apart and segregating the chromosomes. As metabolic organelles, mitochondria are key actors in the metabolic reprogramming of proliferating cells. On the one hand, cell cycle regulators influence mitochondrial metabolism in various ways (Leal-Esteban & Fajas, 2020). For example, CDK1 phosphorylates components of the respiratory chain during G2 and of the mitochondrial translocase of the outer membrane during mitosis, probably to enhance oxidative respiration and ATP production (Harbauer et al, 2014; Wang et al, 2014). On the other hand, energy deficiency is sensed by cell cycle checkpoints causing cell cycle arrest (Mandal et al, 2005; Salazar-Roa & Malumbres, 2017). Mitochondrial dynamics is also intimately linked to cell cycle progression. A hyperfused mitochondrial network is important for the G1-S transition, while mitochondria must fragment before cells enter mitosis (Mitra et al, 2009). Therefore, proliferating cells depend on several coordinated mechanisms to regulate how mitochondria utilize nutrients to fuel cell growth or energy production during the cell cycle. However, how mitochondrial metabolism and respiratory function are coordinated during the cell cycle is still largely unclear. Unravelling these mechanisms is crucial since they are often dysregulated in cancer.

One of the ways how mitochondrial metabolism can be rewired is through regulation of RNA regulons by RNA-binding proteins (Schatton & Rugarli, 2018). CLUH (clustered mitochondria homologue) is a conserved RNA-binding protein, which binds transcripts encoding proteins involved in the respiratory chain, the TCA cycle, and other mitochondrial metabolic pathways

(Gao et al, 2014). Upon loss of CLUH, target mRNAs are subjected to faster decay and their respective proteins are decreased in abundance (Schatton et al, 2017). This leads to alterations in mitochondrial distribution (mitochondrial clustering as the gene name alludes to) mitochondrial cristae integrity, respiratory defects, loss of mtDNA, and decreased activity of TCA cycle enzymes (Schatton et al, 2017; Wakim et al, 2017; Pla-Martin et al, 2020). In the mouse, constitutive loss of *Cluh* causes neonatal lethality, while a liver-specific *Cluh* knock-out (KO) led to hypoglycemia and defective ketogenesis upon starvation (Schatton et al, 2017). CLUH and its target mRNAs form ribonucleoprotein particles in primary hepatocytes. These CLUH granules are important not only to protect target mRNAs from degradation, but also to restrict mTORC1 activation and promote mitophagy (Pla-Martin et al, 2020). Thus, in post-mitotic hepatocytes CLUH controls the balance between catabolism and anabolism, allowing a survival response to starvation.

Astrin (also called SPAG5) is a multifunctional protein with a well-established role during mitosis. The complex astrin/kinastrin/DYNLL1 is involved in the stabilization of the kinetochore-microtubule interactions in metaphase (Kern et al, 2017). Consistently, cells lacking astrin or its interactor kinastrin show defects in chromosome segregations and a delayed metaphase to anaphase progression (Gruber et al, 2002; Dunsch et al, 2011). Astrin has however other roles in interphase, ranging from mTORC1 inhibition (Thedieck et al, 2013), centrosome integrity and centriole duplication (Thein et al, 2007; Kodani et al, 2015), and regulation of p53 levels during G2 after DNA damage (Halim et al, 2013). Astrin is highly expressed in several cancers and it is considered a poor prognostic marker (Yuan et al, 2014; Abdel-Fatah et al, 2016; Bertucci et al, 2016; Zhou et al, 2018; Ying et al, 2020).

We show here that in HeLa cells astrin exists in two isoforms, astrin-1 and astrin-2. We reveal that CLUH binds the *SPAG5* mRNA, as well as the astrin-1 protein. The interaction of CLUH and astrin-1 occurs during interphase and protects astrin-1 and kinastrin from degradation.

Moreover, we show that CLUH positively regulates mitochondrial anaplerotic pathways that sustain mTORC1 activation. Our data disclose a role of CLUH in coupling mitochondrial metabolism to cell cycle progression.

Results

CLUH interacts with astrin-1 and kinastrin

We previously showed that CLUH binds several mRNAs for mitochondrial proteins (Gao et al, 2014). However, among CLUH-bound transcripts, we found *SPAG5* encoding astrin, a multifunctional protein involved in metaphase to anaphase progression, centrosome integrity and mTORC1 regulation (Gruber et al, 2002; Thein et al, 2007; Schmidt et al, 2010; Dunsch et al, 2011; Thedieck et al, 2013; Gao et al, 2014; Kodani et al, 2015). Surprisingly, we also detected astrin as an RNA-independent interactor of endogenous CLUH in a pull-down experiment in HeLa cells after stable isotope labeling in cell culture (SILAC) followed by mass spectrometry (Supplementary Table 1). Reciprocal immunoprecipitations (IPs) using antibodies against human CLUH and astrin, followed by western blot, confirmed the interaction (Figure 1A). Binding was also validated between CLUH and kinastrin (also known as SKAP), a known astrin interactor (Figure 1B) (Schmidt et al, 2010; Dunsch et al, 2011).

Astrin appears as two isoforms (hereafter referred to as astrin-1 and astrin-2) in western blots, and CLUH interacts preferentially with the slower migrating isoform, astrin-1 (Figure 1A). The existence of these two isoforms has been reported in the literature but their identity remains enigmatic. On closer inspection of the *SPAG5* mRNA, we noticed the presence of five in-frame ATGs downstream of the first ATG (hereafter referred to as ATG2-6), which could serve as alternative translation start codons (with moderate and good Kozak sequences) (Figure 1C). Moreover, an upstream ORF within the *SPAG5* 5' UTR (Figure 1C) could influence translation from the downstream ATGs as reported for other genes (Morris & Geballe, 2000; Young &

Wek, 2016). To test these hypotheses, we produced different constructs expressing the 5' UTR and the coding region of the *SPAG5* cDNA, and we mutagenized the uATG, the ATG1 or downstream ATGs individually or in different combinations to GGG (Figure 1-figure supplement 1A). When we expressed the uATG^{GGG}-SPAG5 construct, the expression of astrin-2 was suppressed (Figure 1D). Furthermore, mutagenesis of ATG1 confirmed the existence of a downstream alternative translation start site (Figure 1D). Overexpression of the constructs harboring mutagenized downstream ATGs revealed that astrin-2 is the product of alternative translation starting from ATG3-5 (Figure 1E). The identity of astrin-1 was also confirmed by pull-down of this isoform only using an antibody directed against the N-terminal region of the protein (Figure 1-figure supplement 1B).

To evaluate whether the interaction domain of astrin that binds to CLUH lies in the N-terminal part of astrin-1, we transfected a construct expressing both astrin-1 and astrin-2 (ATG1-SPAG5, Figure 1-figure supplement 1A) or an N-terminus deleted variant (Δ 151-SPAG5, Figure 1-figure supplement 1A) and performed reciprocal IPs in HeLa wildtype and *CLUH* KO cells (Wakim et al, 2017) (Figure 1F). An interaction was observed only with full-length astrin, proving that CLUH binds within the N-terminus of astrin-1 (Figure 1F). In contrast, the astrin interactor kinastrin has no binding preference to any of the two astrin isoforms, consistent with the previously mapped interaction domain between these two proteins (residues 482-693 of astrin) (Figure 1-figure supplement 1C) (Dunsch et al, 2011; Friese et al, 2016; Kern et al, 2016; Kern et al, 2017). CLUH still interacts with astrin-1 upon kinastrin depletion, suggesting that kinastrin is not required for the interaction (Figure 1-figure supplement 1D). In polysome profiles performed after chemical crosslinking, CLUH migrated in lighter fractions, as well as in fractions containing the monosome and polysomes (Figure 1G). In contrast, astrin and kinastrin were only detected in the lighter fractions (Figure 1G).

Figure 1. CLUH interacts with astrin-1 and kinastrin.

(A, B) Western blots of reciprocal co-IPs of endogenous CLUH, astrin and kinastrin in HeLa cells. Two different antibodies have been used to pull down CLUH (1, 2). Asterisks mark IgG light chain. (C) Scheme of human *SPAG5* cDNA with indicated UTRs and ORFs. Close up shows positions of the uATG and ATG1-6 with surrounding Kozak sequences. (D, E) Western blots of HeLa cells overexpressing FLAG-tagged astrin constructs. Pan-actin was used as loading control. (F) Western blots of reciprocal co-IPs of endogenous CLUH and overexpressed FLAG-tagged astrin full length (ATG1-SPAG5) or a N-terminal deleted variant (Δ 151-SPAG5) in WT and *CLUH* KO HeLa cells. Pan-actin was used as loading control for input samples. Asterisks indicate additional astrin bands appearing upon overexpression of the N-terminal deleted variant. (G) Polysome profiling of HeLa cells chemically crosslinked with DSP. At the top, absorbance profile at 254 nm of the fractions is shown with indicated peaks of 40S and 60S ribosomal subunits, 80S monosome and polysomes; at the bottom the corresponding western blots of the fractions are shown. RPL7 was used as a marker for ribosomes.

In conclusion, we identify the expression of two astrin isoforms via alternative initiation of translation, and establish CLUH as a specific molecular partner of astrin-1.

CLUH controls astrin-1 and kinastrin stability and astrin expression

In absence of CLUH, kinastrin and astrin-1, but not astrin-2, are decreased in abundance (Figure 2A). To investigate whether CLUH influences the stability of its interaction partners, we performed a cycloheximide (CHX) chase in wildtype and *CLUH* KO HeLa cells (Figure 2A). In absence of CLUH, kinastrin and astrin-1, but not astrin-2, are highly unstable (Figure 2A-D). The instability of astrin in absence of CLUH was confirmed in *Cluh* KO MEFs which only express the larger isoform of astrin (Figure 2-figure supplement 1A, B). Inhibition of the proteasome by MG132 treatment in *CLUH* KO HeLa cells fully rescued kinastrin and partially astrin-1 levels (Figure 2A, E-G). Decreased kinastrin levels upon astrin depletion have already been reported (Schmidt et al, 2010; Dunsch et al, 2011).

The underlying reason for the only partial rescue of astrin-1 might be another level of regulation by CLUH. Given the identification of *SPAG5* mRNA as a CLUH target (Gao et al, 2014), we tested if CLUH is involved in astrin synthesis. To this end, we immunoprecipitated newly

synthesized astrin in wildtype and *CLUH* KO cells after labeling with ³⁵S methionine for different time points (Figure 2H-I). We observed that *CLUH* regulates the synthesis of astrin-1 (Figure 2H-I). *CLUH* controls the expression of some of its target mRNAs by preventing their degradation (Schatten et al., 2017). To elucidate whether this is also the case for *SPAG5*, we labeled newly synthesized RNA with the uridine analog ethynyl uridine (EU) and chased it for 8 h. We precipitated the EU-RNA with biotin-azide using Click-iT chemistry and quantified *SPAG5* mRNA levels with qRT-PCR. *SPAG5* mRNA was less stable in absence of *CLUH*, whereas steady state levels and EU incorporation were unaffected (Figure 2J-L).

Figure 2. CLUH controls astrin-1 and kinastrin stability and astrin expression.

(A) Western blots of WT and *CLUH* KO HeLa cells treated with CHX for indicated time points with or w/o additional MG132 treatment. Ponceau S staining was used as loading control. (B-D) Quantification of CHX chase western blots as shown in A (n=3 independent experiments). Two-way ANOVA with post hoc Tukey's multiple comparison tests were performed with $P \leq 0.05$: *, $P \leq 0.01$: **, $P \leq 0.001$: ***. Genotype x time interaction significance is also shown. Error bars represent SEM. (E-G) Quantification of proteins levels after 8 h CHX treatment of western blots as shown in A (n=3 independent experiments). Bars show the mean $\pm$ SEM. Dotted lines indicate protein levels at 0h time points. One-way ANOVA with post hoc Tukey's multiple comparison tests were performed with $P \leq 0.05$: *. (H) Autoradiograms of IP of newly synthesized astrin labeled with ^{35}S -methionine for indicated time points in WT and *CLUH* KO HeLa cells. (I) Quantification of immunoprecipitated newly synthesized astrin after 60 min labeling of experiments as shown in H (n=3 independent experiments). Bars show the mean $\pm$ SEM. Two-tailed paired Student's t-test was performed with $P \leq 0.05$: *. (J) Steady state mRNA levels of *SPAG5* in WT and *CLUH* KO HeLa cells (n=4 independent experiments). Bars show mean $\pm$ SEM. *RPL13* levels have been used for normalization. (K, L) Levels of EU-incorporation (K) and mRNA decay (L) of *SPAG5* mRNA in WT and *CLUH* KO HeLa cells after specific labeling and pull down of newly synthesized RNA (n=4 independent experiments). *GAPDH* levels have been used for normalization. Calculated half-lives are indicated. Bars show the mean $\pm$ SEM. Two-tailed paired Student's t-test was performed with $P \leq 0.05$: *.

In conclusion, our data reveal that *CLUH* controls the expression of astrin-1 at multiple levels, by binding and stabilizing its mRNA, by affecting its synthesis, and maintaining its stability.

***CLUH* binds astrin-1 in interphase**

Astrin controls cell cycle progression at various stages, raising the question if the complex *CLUH*-astrin-1 is cell cycle-dependent. To this end, we immunoprecipitated *CLUH* from cells enriched in different phases of the cell cycle (Figure 3A, Figure 3-supplement 1A). The effective synchronization of the cells was confirmed by analyzing the input levels of cyclin D3 (G2 phase marker), pH3-Ser10 (M phase marker) and pRPS6-Ser235/236 (inhibited upon starvation) (Figure 3A). Astrin-1, but not astrin-2, was more abundant in S and G2, while *CLUH* levels were similar in the different phases of the cell cycle (Figure 3A). Both astrin isoforms are phosphorylated at multiple sites, leading to slower migration in SDS-PAGE in prometaphase (PM) (Figure 3A) (Chang et al, 2001; Cheng et al, 2008; Chiu et al, 2014; Chung

et al, 2016; Geraghty et al, 2021). The CLUH/astrin-1 complex is enriched in S and G2 phases but not detected in PM, indicating that CLUH preferentially interacts with unmodified astrin-1 in interphase and that the interaction might be controlled by the phosphorylation status of astrin (Figure 3A).

Figure 3. The astrin-1/CLUH complex is enriched in interphase.

(A) Western blots of co-IPs of endogenous CLUH in WT and *CLUH* KO HeLa cells. Cells have been synchronized as shown in Figure 3-figure supplement 1A. Pan-actin was used as loading control and cyclin D3 as G2 phase marker, pH3-Ser10 as M phase marker and pRPS6-Ser235/236 to assess effective starvation of input samples. (B) Enriched proteins immunoprecipitated with an antibody against endogenous CLUH in G2-synchronized HeLa cells and detected by mass spectrometry (n=4 independent replicates). Highlighted are all proteins enriched with a $\log_2FC \geq 3$ and $q \leq 0.05$. Marked in green are centrosomal proteins; marked in red are previously identified astrin/kinastarin interactors. (C) GO cellular component analysis of enriched proteins highlighted in B analyzed using the EnrichR webtool.

To fully capture the CLUH interactome, we performed four biological independent IPs of CLUH in G2-synchronized wildtype cells followed by label-free mass spectrometry (Figure 3B, Figure 3-figure supplement 1A). The correct synchronization was confirmed by propidium iodide (PI) staining followed by flow cytometry (Figure 3-figure supplement 1B, C). This experiment confirmed astrin-1 and kinastrin as highly enriched interactors of CLUH (Figure 3B and Supplementary Table 2). In addition, proteins previously shown to be part of the astrin/kinastrin complex, such as MYCBP, or linking the complex to the microtubule cytoskeleton were also detected in the precipitate. Among these proteins are CLASP1 and 2, two microtubule plus-end binding proteins, and DYNLL1, a retrograde motor protein (Manning et al, 2010; Schmidt et al, 2010; Dunsch et al, 2011; Kern et al, 2016; Kern et al, 2017) (Figure 3B). Interestingly, among top CLUH interactors, we found the centrosomal proteins CEP170B and CEP44, indicating a link of CLUH with the centrosome and the microtubules (Figure 3B, C).

Astrin-1 regulates the subcellular localization of CLUH

The previous data strongly indicate the existence of a pool of CLUH that interacts with microtubular structures, including centrosomes. We tested the role of astrin-1 in defining the subcellular localization of CLUH. Overexpression of astrin-1, but not of astrin-2, recruited endogenous CLUH to a perinuclear formation (Figure 4A). These formations are γ -tubulin positive (Figure 4B, C), in line with the reported localization of astrin to the centrosome and the pericentriolar region (Cheng et al, 2007; Thein et al, 2007; Kodani et al, 2015). To substantiate the hypothesis that astrin-1 controls CLUH subcellular localization, we derived a monoclonal cell line completely devoid of astrin expression (referred to as *SPAG5* KO) (Figure 4D). CLUH staining was overtly different in these cells, showing a characteristic accumulation in peripheral granular structures in a high percentage of cells (Figure 4E, F). These structures were also positive for vinculin, a marker of focal adhesions (Figure 4E). These findings are

consistent with a role of astrin-1 in regulating the localization to the centrosomes of a pool of CLUH.

Figure 4. Astrin-1 controls CLUH subcellular localization.

(A-C) Confocal immunofluorescence pictures of HeLa cells overexpressing FLAG-tagged astrin-1 and astrin-2 (SPAG5), astrin-1 (ATG3+4+5^{GGG}-SPAG5) or astrin-2 (ATG1^{GGG}-SPAG5) alone stained for FLAG (green) and CLUH (red) (A) or γ -tubulin (green) and FLAG (red) (B) or γ -tubulin (green) and CLUH (red) (C). DAPI was used to stain nuclei (blue). Cells were fixed with 4%PFA/PBS (A) or ice-cold methanol (B, C). Scale bar, 10 μ m. (D) Western blots of WT and SPAG5 KO HeLa clones. Pan-actin was used as loading control. SPAG5 KO clone #2 has been used for experiments in this study. (E) Confocal immunofluorescence pictures of WT ind and SPAG5 KO HeLa cells stained for vinculin

(green) and CLUH (red). DAPI was used to stain nuclei (blue). Scale bar, 10 μ m. (F) Quantification of cells with CLUH-granules of experiments as shown in E (n=4 independent experiments). Bars show mean $\pm$ SEM and dots represent values of individual replicates. At least 160 cells per genotype per replicate have been counted. Two-tailed paired Student's t-test was performed with $P \leq 0.01$: **.

Loss of astrin or kinastrin do not recapitulate CLUH-dependent mitochondrial phenotypes

What is the function of CLUH in complex with astrin-1 and kinastrin? We first asked whether loss of astrin or kinastrin phenocopies CLUH-dependent mitochondrial abnormalities. To avoid possible compensatory effects in stable KO clones, we employed inducible CRISPR-Cas9 astrin and kinastrin KO HeLa cells (hereafter referred to as *SPAG5* and *KNSTRN* ind-KO) in which there is constant expression of sgRNAs complementary to the target genes and the expression of the Cas9 is doxycycline inducible (Kern et al, 2017; McKinley & Cheeseman, 2017). Using this system, we induced an acute deletion of astrin and kinastrin for four days, in many but not all cells (Figure 5-figure supplement 1A, B). We focused on previously reported phenotypes observed in *CLUH* KO cells or tissues, such as mitochondrial clustering, mitochondrial fragmentation, loss of mtDNA, and decreased assembled respiratory complexes (Gao et al, 2014; Schatton et al, 2017; Wakim et al, 2017). Mitochondrial distribution, morphology, ultrastructure and mtDNA levels were indistinguishable in WT, *SPAG5* and *KNSTRN* ind-KO cells (Figure 5A-C, Figure 5-figure supplement 1C-E). Furthermore, respiratory supercomplexes containing complex I and III assembled normally in these cells, and in-gel activity of complex I was similar to control cells (Figure 5D). In contrast, cells lacking CLUH displayed a reduction of assembled supercomplexes I-III, decreased activity of complex I, and abnormal mitochondrial ultrastructure (Figure 5D and Figure 5-figure supplement 1E). These data indicate that CLUH controls mitochondrial function independent from the interaction with astrin-1 or kinastrin.

Figure 5. Astrin and kinastrin depletion does not mimic mitochondrial phenotypes seen upon absence of CLUH.

(A) Mitochondrial network of WT, *SPAG5* and *KNSTRN* ind-KO HeLa cells grown in basal or galactose media for 16 h. Mitochondria were stained with an antibody against TOMM20. Scale bar, 10 μ m. On the left side, confocal immunofluorescence pictures are shown, on the right side, mitochondrial network is shown after segmentation. Color code for different mitochondrial morphologies: purple: filamentous; green: rod-shaped; orange: fragmented; blue: swollen; black: unclassifiable. (B) Quantification of mitochondrial morphology of experiments as shown in A (n=3 independent experiments; at least 66 in basal or 44 cells in galactose have been analyzed per genotype per replicate). Bars show the mean of each morphological class with SEM. (C) mtDNA levels of WT, *SPAG5* and *KNSTRN* ind-KO HeLa cells grown in basal or galactose media for 16 h (n=4 independent experiments). Bars show mean $\pm$ SEM and dots represent values of individual replicates. (D) BN-PAGE analysis of respiratory chain supercomplexes and complex I activity staining of isolated mitochondria of WT, *CLUH* KO and WT, *SPAG5* and *KNSTRN* ind-KO HeLa cells grown in basal or galactose media for 16 h.

Loss of astrin rewires metabolic pathways to promote anabolism

To define how astrin and kinastrin affect cell function, we performed label free quantitative proteomics in *SPAG5* and *KNSTRN* ind-KO cells. In line with the short time of induced KOs, only minor differences in the overall proteome in *SPAG5* and *KNSTRN* ind-KO cells compared to ind-WT cells was observed (Figure 6A and Supplementary Table 3). Notably, CLUH levels were unaffected by the loss of its interactors (Figure 6A and Supplementary Table 3). Astrin depletion caused a slight decrease of proteins encoded by CLUH mRNA targets (Figure 6A; marked in blue). Downregulated KEGG pathways, analyzed using the EnrichR webtool (using a generous cut-off of $p \leq 0.05$; $q \leq 0.15$) (Chen et al, 2013; Kuleshov et al, 2016; Xie et al, 2021), largely overlapped with metabolic pathways affected by CLUH deletion (TCA cycle, fatty acid and amino acid degradation; Figure 6B) (Schatton et al, 2017). Interestingly, metabolic pathways connected to nucleotide biosynthesis (purine and pyrimidine metabolism), the pentose phosphate pathway (PPP) and glycolysis were upregulated (Figure 6C). Furthermore, mTORC1 appeared as one of the most enriched terms in pathway analysis of perturbed proteins (Figure 6-figure supplement 1A, B).

The proteomic profile of *SPAG5* ind-KO cells is consistent with a previous study that identified astrin as a negative regulator of mTORC1 (Thedieck et al, 2013). We confirmed that mTORC1 is hyperactive in *SPAG5* ind-KOs upon starvation for 8 h in HBSS (Figure 6-figure supplement 1C, D). To reveal if this increased signaling is reflected in cell metabolism, we performed targeted metabolomics analysis in *SPAG5* and *KNSTRN* ind-KO cells.

Figure 6. Astrin loss promotes anabolic pathways.

(A) Volcano plot of label-free proteomics of WT and *SPAG5* ind-KO HeLa cells (n=4 independent replicates). CLUH targets are marked in blue. (B, C) KEGG pathways of downregulated (B) or upregulated (C) proteins (with a cut-off of $p \leq 0.05$; $q \leq 0.15$) detected in proteomics analysis of *SPAG5* ind-KO cells (A and Supplementary Table3) using the EnrichR webtool. (D-H) Targeted metabolomics of WT, *SPAG5* and *KNSTRN* ind-KO cells after 8 h HBSS starvation showing glycolytic intermediates and lactic acid (D), sedoheptulose-7-P (E), pyruvic acid and TCA cycle intermediates (F), nucleotide levels (G) and ornithine and polyamine levels (H). Bars show mean $\pm$ SEM and dots represent values of individual replicates. One-way ANOVA with post hoc Tukey's multiple comparison tests on log converted fold changes were performed with $P \leq 0.05$: *, $P \leq 0.01$: **, $P \leq 0.001$: ***.

In agreement with the mild proteomics changes, metabolomics of *SPAG5* ind-KO under basal condition did not reveal major alterations of the pools of glycolytic and TCA cycle intermediates, amino acids, and nucleotides, with the exception of an increase in glutamine, proline, lactate, and citric acid (Figure 6-figure supplement 2A-E). Upon starvation, *SPAG5* depletion led to more prominent alterations of the metabolome, with accumulation of several glycolytic intermediates, lactate, and sedoheptulose-7-phosphate, in agreement with high glycolytic rate and an increase in the PPP (Figure 6D, E). In addition, the TCA cycle intermediates citrate, isocitrate and malate were increased (Figure 6F). Both the TCA cycle and the PPP intermediates are crucial for synthesis of nucleotides, several of which accumulated in astrin-deficient cells (Figure 6G). Amino acid levels were unaffected (Figure 6-figure supplement 2F), with the exception of an increase of ornithine, a precursor of polyamines, which were also more abundant (Figure 6H). *KNSTRN* ind-KO cells did not show detectable metabolic differences to control cells (Figure 6D-H and Figure 6-figure supplement 2A-F). Together, our data show that cells depleted of astrin, despite starvation, engage in anabolic pathways linked to cell growth, in agreement with hyperactivated mTORC1 signaling.

Loss of CLUH impairs anaplerotic and anabolic pathways

Increased mTORC1 signaling upon starvation is also a prerogative of CLUH-deficient cells and tissues (Pla-Martin et al, 2020) (Figure 6-figure supplement 1C, D). Surprisingly, the metabolic

profile of starved *CLUH* KO cells was strikingly different from that of *SPAG5* ind-KO cells (Figure 7A-F). Targeted metabolomics revealed a prominent decrease of the PPP intermediate sedoheptulose-7-phosphate, and a significant increase of pyruvate (Figure 7A-C). The intermediates of the first part of the TCA cycle (citrate, aconitate, and isocitrate) were decreased (Figure 7C). In addition, most amino acids that feed into the TCA cycle were decreased (Figure 7D), including aspartate, which is mainly produced by oxaloacetate and is an important precursor of pyrimidines (Figure 7D). Glutamine was instead elevated, as well as α -ketoglutarate (Figure 7C, D). In addition, cells lacking *CLUH* showed a perturbation of polyamines metabolism, with a prominent reduction of spermidine, and decreased levels of some nucleotides, especially inosine monophosphate (IMP), the first nucleotide in the synthesis pathway of purines (Figure 7E, F). Thus, upon starvation *CLUH* KO cells fail to maintain the TCA cycle intermediates (anaplerosis), and surprisingly show defects also in other anabolic pathways that are linked to cell growth and are regulated by mTORC1. This metabolic profile is strikingly opposite to that of *SPAG5* ind-KO cells, and indicate that the mTORC1 hyperactivation in absence of *CLUH* is not reflected in the cellular metabolic rewiring. This data points to an important role of *CLUH* in the mTORC1-dependent rewiring of cellular metabolism, by supporting mitochondrial anaplerotic pathways.

Figure 7. Depletion of CLUH impairs anabolic pathways.

(A-F) Targeted metabolomics of WT and *CLUH* KO HeLa cells after 8h HBSS starvation showing glycolytic intermediates and lactic acid (A), sedoheptulose-7-P (B), pyruvic acid and TCA cycle intermediates (C), amino acid levels (D), ornithine and polyamine levels (E) and nucleotide levels (F). Bars show mean $\pm$ SEM and dots represent values of individual replicates. Two-tailed unpaired Student's t-tests on log converted fold changes were performed with $P \leq 0.05$: *; $P \leq 0.01$: **; $P \leq 0.001$: ***.

CLUH controls cell cycle progression

In proliferating cells mitochondrial metabolism is constantly adapted to the specific metabolic needs of the different cell cycle phases. Metabolomic analyses during starvation (a treatment that arrests cell proliferation and blocks entry in G2/M) have revealed opposite signatures in cells lacking CLUH or astrin, indicating a perturbed metabolic rewiring. We therefore hypothesized that the functional significance of the interaction of CLUH with astrin and of their reciprocal regulation is to couple mitochondrial metabolism to cell cycle progression. To investigate this possibility, we synchronized wildtype and *CLUH* KO HeLa cells using a double thymidine block (DTB) followed by release for different time points (Figure 8A). To determine the different phases of cell cycle we stained the cells with the DNA dye PI and analyzed them by flow cytometry. *CLUH* KO cells showed different dynamics in cell cycle progression compared to wildtype cells (significant changes in genotype x time in G0/G1, S and G2/M phases; Figure 8B-D). During all time points, slightly more *CLUH* KO cells were in G0/G1 phase and less in S and G2/M (Figure 8B-D). Surprisingly, *CLUH* KO cells cycled faster than control cells, with more cells already in G2/M 3 h after the release and more cells entering the next cell cycle at 8 h after release (Figure 8B-E). Consistently, the dynamics of several cell cycle markers was perturbed in *CLUH* KO cells, including precocious phosphorylation of retinoblastoma (p-RB1-Ser807/811) and accumulation of cyclin D3 (Figure 8F). In addition, the inactivating phosphorylation of CDK1 on Tyr15, which occurs in G2 and allows progression into M, showed a different temporal profile (Figure 8F). During G1 the cells double their mass before progressing to M phase and dividing into two daughter cells. *CLUH* KO cells showed a reduced cell size at all time points during the release, in agreement with the defective growth pathways detected by the metabolomics (Figure 8G). Thus, upon loss of CLUH, HeLa cells escape the growth and energy check-point at the end of G1 and proceed faster through the cell cycle. Our results thus identify CLUH as a novel coordinator of mitochondrial activity with the cell cycle progression (Figure 8-figure supplement 1).

Figure 8. CLUH controls cell cycle progression at the G1/S boundary.

(A) DTB synchronization protocol used for cell cycle progression analysis. Cells were collected after release of 2nd thymidine block at indicated time points. (B-E) Percentage of WT and *CLUH* KO HeLa cells in G0/G1 (B) in S (C) and G2/M phase (D) and cell cycle distribution analysis (E) after DTB synchronization, collection at indicated time points and PI staining followed by flow cytometric analysis (n=3 independent experiments). For B-D, two-way ANOVA with post hoc Tukey's multiple comparison tests were performed with $P \leq 0.05$: *; $P \leq 0.01$: **; $P \leq 0.001$: ***. Genotype x time interaction significance is also shown. Graphs and bars show mean $\pm$ SEM. (F) Western blots of WT and *CLUH* KO HeLa cells collected after

DTB synchronization at indicated time points. Pan-actin was used as loading control. (G) Cell size analysis of WT and *CLUH* KO HeLa cells of experiments shown in B-E. Bars show mean $\pm$ SEM and dots represent values of individual replicates. Two-tailed paired Student's t-tests were performed with $P \leq 0.05$: *; $P \leq 0.01$: **.

DISCUSSION

We have uncovered a role of CLUH in integrating mitochondrial metabolism with cell cycle progression. Mechanistically, CLUH controls the synthesis and the stability of astrin-1, the full-length protein product of the *SPAG5* gene. Astrin is a coiled-coil protein, with a well-established role during mitosis to stabilize kinetochore-microtubule interactions and allow correct orientation of chromosomes at the metaphase plate (Manning et al, 2010; Dunsch et al, 2011; Kern et al, 2017; Ying et al, 2020). Moreover, additional roles of astrin have been reported in interphase, including mTORC1 inhibition (Thedieck et al, 2013), centriole duplication (Kodani et al, 2015), and the recovery from DNA damage at the G2/M transition (Halim et al, 2013). We show here that the interaction of CLUH with astrin is regulated during the cell cycle, and ensures the matching of the mitochondrial metabolic output with the progression of the cell cycle.

SPAG5 upregulation in several cancers has been associated with poor prognosis (Yuan et al, 2014; Abdel-Fatah et al, 2016; Bertucci et al, 2016; Zhou et al, 2018; Li et al, 2019). Human cancer cell lines show the expression of two isoforms of astrin, however the origin of these isoforms has not been investigated up to now. We demonstrate that the two astrin isoforms arise by alternative translation initiation, and are regulated by the presence of an uORF and downstream AUGs with good Kozak sequences. Intriguingly, CLUH interacts only with the full-length astrin-1 protein. The N-terminal region of astrin is an unstructured domain that is dispensable for interaction with kinastrin, DYNLL1, MYCBP and the kinetochore (Kern et al, 2017). Recently, the PLK1 kinase has been shown to interact with and phosphorylate the astrin

N-terminus, an important step to stabilize the kinetochore-microtubule attachment (Geraghty et al, 2021). Based on our findings, we speculate that N-terminal phosphorylations are responsible for the lack of interaction of CLUH and astrin-1 in prometaphase. Thus, astrin detaches from CLUH during mitosis when it is required for metaphase to anaphase progression.

Interestingly, CLUH appears to regulate astrin-1 expression at multiple levels. The *SPAG5* transcript represents an exception to the finding that mRNAs bound by CLUH mainly encode mitochondrial proteins (Gao et al, 2014). We show here that the *SPAG5* mRNA decays faster and that the synthesis of astrin-1 is impaired in absence of CLUH. It is known that during cytokinesis the E3-ubiquitin ligase MID2 ubiquitinates astrin, targeting it for proteosomal degradation (Gholkar et al, 2016). CLUH may be implicated in supporting synthesis of astrin-1 to replenish its levels in G1. Astrin-1 then accumulates during the S and G2 phases of the cell cycle and is stabilized, together with kinastrin, by binding CLUH.

The interaction of CLUH with astrin-1 led us first to investigate the possibility of a role of astrin-1 in concert with CLUH in regulating mitochondrial metabolism. Our data do not support this scenario, since depletion of astrin or kinastrin do not recapitulate the prominent mitochondrial defects observed upon CLUH downregulation or knock-out. Upon loss of astrin or kinastrin, mitochondria are normally dispersed in the cytoplasm, show normal morphology and ultrastructure, do not lose mtDNA and efficiently assemble respiratory supercomplexes. *SPAG5* ind-KO cells showed a mild decrease of the levels of mitochondrial proteins encoded by CLUH target mRNAs. Furthermore, starved cells lacking astrin or CLUH display strikingly opposite metabolic profiles. Finally, astrin and kinastrin are not detected in polysomal fractions, in contrast to CLUH.

Our data establish an essential role of CLUH in the metabolic rewiring directed by mTORC1 signaling. Upon starvation, both *CLUH* KO and *SPAG5* ind-KO cells showed inappropriate

mTORC1 activation, in agreement with astrin being a negative regulator of mTORC1 (Thedieck et al, 2013). However, the metabolic defects caused by loss of CLUH were discordant with this signaling, with a decrease in the TCA cycle intermediates and in the pool of glycolytic intermediates, some nucleotides, and polyamines. Enzymes of the TCA cycle as well as characteristic anaplerotic enzymes, such as pyruvate carboxylase, propionyl-CoA carboxylase and other branched amino-acid catabolic enzymes are encoded by *bona fide* CLUH target mRNAs (Gao et al, 2014). These pathways are essential to replenish the TCA cycle intermediates to compensate for their loss upon activation of biosynthetic pathways following mTORC1 signaling. Indeed, a compensatory increase in anaplerotic pathways occurs under conditions of chronic mTORC1 activation (Dutchak et al, 2018). Therefore, CLUH tunes mTORC1 signaling in two independent ways, by regulating the expression of astrin-1 and by ensuring the maintenance of mitochondrial anaplerotic pathways via its RNA-binding function (Figure 8-figure supplement 1). Our data demonstrate another connection between mTORC1 signaling and mitochondrial function. mTORC1 positively regulates the translation of mitochondrial proteins involved in oxidative phosphorylation and mitochondrial dynamics (Morita et al, 2013; Morita et al, 2017), while inhibition of mTORC1 activates a lipid signaling cascade that triggers YME1L-mediated intramitochondrial proteolysis to limit mitochondrial biogenesis (MacVicar et al, 2019). Furthermore, mTORC1 hyperactivation is part of the integrated stress response that follows mitochondrial dysfunction (Khan et al, 2017).

Proliferating cells must shunt metabolites into mitochondrial pathways that promote cell growth or oxidative respiration and ATP production, depending on the cell cycle phase (DeBerardinis et al, 2008; Salazar-Roa & Malumbres, 2017). In G1 cells double their mass and depend on glycolysis to fuel the TCA cycle and sustain biosynthetic pathways, while in S synthesis of nucleotides is required and glutamine oxidation is prevalent. Interestingly, the TCA cycle intermediates fluctuate during the cell cycle, and it is known that these variations are not

transcriptionally regulated (Olsen et al, 2010; Ahn et al, 2017). In mammalian cells, mTORC1 activation is important for the transition from G1 to S, an important check point when the energy levels and the growth status of the cell are sensed, and from G2 to M (Cuyàs et al, 2014). We hypothesize that by regulating astrin-1 and stabilizing an RNA regulon involved in the TCA cycle and anaplerotic pathways (Gao et al, 2014), CLUH ensures that the progression of the cell cycle is adjusted with activation of mTORC1 signaling and the mitochondrial metabolic profile (Figure 8-figure supplement 1). Using a post-transcriptional mechanism to coordinate mitochondrial function with cell cycle phases allows a fast and flexible mean to control a broad gene program. Consistently, cells lacking CLUH have cell cycle defects, characterized by a faster cell cycle progression despite failure to properly double the cell mass.

Our data not only support a role of CLUH to sustain the mTORC1 signaling cascade, but reveal astrin-1 as a negative regulator of CLUH. Astrin dynamically regulates CLUH subcellular localization: astrin-1 overexpression depletes endogenous CLUH from the cytoplasm and recruits it around the centrosome, while *SPAG5* KO cells show an enrichment of CLUH in structures that contain focal adhesion markers at the plasma membrane. Intriguingly, one study has recently shown that the spatial association of mTORC1 to focal adhesions is not only necessary but also sufficient for the cellular response to growth-promoting signals (Rabanal-Ruiz et al, 2021). Thus, by binding the *SPAG5* mRNA and controlling the stability of astrin-1, CLUH regulates its own subcellular distribution and physiological function. These kinds of feedbacks are commonly operating in metabolic circuits that need to respond to external stimuli, and then recover the original status. It is possible that by sequestering CLUH at the centrosome, astrin-1 puts a break on mTORC1 signaling.

More work is needed to characterize the composition and role of the peripheral CLUH structures that we observe upon astrin depletion. Currently, we do not know if these structures contain mRNAs, are translationally active, or recruit mTORC1 components. Moreover, the

question arises of the role of CLUH recruitment at the centrosome, which is also strongly supported by the finding of other centrosomal proteins, besides astrin-1, as CLUH molecular partners. Astrin is a component of centriolar satellites in interphase, and it is required for the centrosomal localization of CDK5RAP2, a protein involved in microcephaly, and for proper centriole duplication in S phase (Thein et al, 2007; Kodani et al, 2015), a step which is crucial for cell cycle progression. By recruiting CLUH at the centrosome, astrin may confer a novel signaling role to this organelle, by dynamically relying information on the mitochondrial metabolic status to match it with the progression of the cell cycle. Whether also mRNAs bound to CLUH are recruited to the centrosome is a question to be explored in the future. Finally, our data add to the evidence that astrin plays additional roles outside mitosis. Astrin was also identified in an unbiased screen to be essential for the reentry in mitosis after DNA damage (Halim et al, 2018). This interphase role of astrin should be further explored in view of our findings, as possibly involving dysregulated or enhanced CLUH activity.

HeLa cells, as many human cancer cells, overexpress not only astrin-1 but also astrin-2, an isoform of astrin competent to bind all other interactors (kinastrin, DYLN1 and MYCPB) and the kinetochore (Kern et al, 2017), but not CLUH. We propose that expression of astrin-2 endows cancer cells with the ability to proliferate, despite a dysregulated coupling between mitochondrial metabolism and the cell cycle, making CLUH a possible novel therapeutic target in cancers overexpressing *SPAG5*. In conclusions, our findings reveal a novel post-transcriptional mechanism coordinating mitochondrial metabolism and the cell cycle.

MATERIAL AND METHODS

Cell lines

HeLa WT and *CLUH* KO cells and immortalized WT and *Cluh* KO MEFs were previously described (Gao et al, 2014; Wakim et al, 2017). Doxycycline inducible CRISPR-Cas9 HeLa WT, *SPAG5* and *KNSTRN* KO cells (Kern et al, 2017; McKinley & Cheeseman, 2017) were kindly provided by Iain Cheeseman (Whitehead Institute for Biomedical Research, Cambridge, USA). To produce inducible HEK293T cells stably expressing 3xFLAG-kinastrin, full length N-terminally 3xFLAG tagged human *KNSTRN* ORF was cloned into pTREx-DEST30 vector by serial Gateway recombinations (Invitrogen) according to the manual. Stable transfected HEK293T cells were generated with the Flp-In T-REx 293 cell system (Invitrogen) following the manual. Positive cells were selected with media containing 1.5 mg/mL hygromycin (InvivoGen) and 150 µg/mL blasticidin (InvivoGen) starting 24h after transfection and single colonies were picked to generate a monoclonal cell line.

Cell culture

All cells were cultured at 37°C and 5% constant CO₂ supply. All cell culture media and ingredients were purchased from Gibco unless stated otherwise. HeLa cells and MEFs were grown in Dulbecco's modified eagle medium (DMEM) including 4.5 g/L glucose supplemented with 2 mM L-glutamine, 2% penicillin (10,000 u/mL)/ streptomycin (10,000 µg/mL) and 10% FetalClone III serum (Hyclone, Thermo Fisher Scientific). HEK293T cells were cultured in DMEM including 4.5 g/L glucose supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids, 10% tetracycline free fetal bovine serum (Biocrom AG), 1.5 mg/mL hygromycin and 150 µg/mL blasticidin. To induce overexpression, cells were treated with 1 µg/mL tetracycline (Sigma-Aldrich) for 16h. Doxycycline inducible CRISPR-Cas9 HeLa WT, *SPAG5* and *KNSTRN* KO cells were grown in DMEM containing 4.5g/L

glucose supplemented with 2 mM L-glutamine, 2% penicillin (10,000 u/mL)/ streptomycin (10,000 µg/mL) and 10% tetracycline free fetal bovine serum (Sigma-Aldrich). To induce Cas9 expression, cells were treated with 1 µg/mL doxycycline (Sigma-Aldrich) for four consecutive days adding fresh doxycycline each day. To obtain stable *SPAG5* and *KNSTRN* KO cell lines, induced cells underwent monoclonal selection after serial dilutions.

Metabolic labeling

For metabolic labelling of newly synthesized astrin, cells were primed in metabolic labeling medium [DMEM containing 4.5 g/L glucose without L-methionine and L-cystine (#21013024, Gibco) including 10% dialysed serum, 2% penicillin (10,000 u/mL)/ streptomycin (10,000 µg/mL), 2 mM L-glutamine, 1 mM sodium pyruvate and 1% non-essential amino acids] for 30 min followed by incubation with metabolic labeling medium including ³⁵S-methionine (50 µCi per 10 cm plate) for indicated time points.

SILAC labeling

Cells were cultured in DMEM medium without glutamine, arginine and lysine (Silantes, # 280001200), supplemented with 2 mM L-glutamine, 2% penicillin/ streptomycin, dialyzed FCS (Thermofisher, # 26400044), 28 µg/mL L-arginine-HCl (Arg0 or Arg10) (Silantes, # 201604102) and 73 µg/mL L-lysine-2HCl (Lys0 or Lys8) (Silantes, # 211604102) for three passages before collecting for IP.

CHX chase and galactose treatment

To assess protein stability, cells were treated with 0.1 mg/mL CHX (Sigma-Aldrich) with or without 20 µM MG132 (Sigma-Aldrich) for indicated time points. Cells were grown when indicated in galactose media [DMEM, no glucose (#11966-025, Gibco) supplemented with 10 mM galactose (Sigma-Aldrich), 2 mM L-glutamine, 1 mM sodium pyruvate, 2% penicillin

(10,000 u/mL)/ streptomycin (10,000 µg/mL) and 10% dialyzed fetal bovine serum (Gibco)]
for 16 h before experiments were performed.

Cloning and mutagenesis of SPAG5 constructs

The underlying sequence of human *SPAG5* used in this study can be found under the accession number NM_006461.3 on the NCBI database. Human full length *SPAG5* ORF (ATG1-SPAG5) or excluding the first 453 nucleotides (Δ 151-SPAG5) were cloned into p3xFLAG-CMV-14 (Sigma-Aldrich) using NotI or NotI/ClaI restriction sites, respectively. To obtain a construct including the 5' UTR (5UTR-SPAG5), the 5' UTR of *SPAG5* was cloned into Δ 151-SPAG5-FLAG using HindIII restriction site. To mutagenize ATGs to GGG, DpnI site directed mutagenesis was employed. Mutagenized base pair positions and construct names are indicated in Figure 1C and S1A.

Cell transfection

Cells were transfected with Lipofectamine 2000 (Invitrogen) in a plasmid to transfection reagent ratio of 1:5 according to the manual. After 24 h of overexpression, cells were harvested by scraping and pelleting for lysis or fixed with respective reagent for immunofluorescence. RNA interference of *CLUH* was done as described before (Gao et al, 2014). Briefly, HeLa cells were transfected with 100 nM of siRNA against human *CLUH* or control siRNA using Lipofectamine 2000 according to the instructions of the manual and experiments were performed after 72h of downregulation.

Polysome profiling

Cells were grown in 15 cm dishes to 70-80% confluency and treated for 15 min with fresh media supplied with 100 µg/mL CHX (Sigma Aldrich), followed by crosslinking with 1 mM dithiobis (succinimidyl propionate) (DSP) in PBS for 30 min at RT. prior to polysome profiling

followed by immunoblotting. Cells were washed with PBS and quenched in 20 mM Tris-HCl, pH 7.4, 5 mM L-cysteine for 10 min. Cells were then washed twice with ice cold PBS containing 100 µg/mL CHX and scraped in 1.5 mL ice cold PBS including CHX and collected in a 2 mL tube. Cells were immediately centrifuged at 21,000 x g for 10 sec at 4°C and supernatant was discarded. Cells were lysed for 30 min on ice in buffer comprised of 20 mM Tris-HCl, pH 7.4, 30 mM KCl, 15 mM MgCl₂, 0.5% Triton X-100 (vol/vol), 2 mM DTT, 1 mg/mL heparin, 100 µg/mL CHX, 0.16 U/mL RNase inhibitor (RNasin Plus; Promega), and 1× EDTA-free protease cocktail (Roche). Cell debris were then removed with 5 min centrifugation at 14 000 x g at 4°C and protein concentration was measured with the standard Bradford assay. Cell lysate was then applied on a continuous 7-47% sucrose gradient (mol weight/volume) in ultra clear tubes (Beckman & Coulter, #331372) and centrifuged at 97,658 x g for 3 h at 4°C using a SW41Ti rotor (Beckman & Coulter, # 331362). The polysome fractions were collected using the Foxy R1 Fraction Collector and immediately snap frozen with liquid nitrogen and stored at -80 °C. The polysome profile was detected with the UA-6 detector (Teledyne ISCO) during the collection of each polysome fraction.

Synchronization of cells

Cells were synchronized by double thymidine block (DTB) using an adapted protocol (Dai et al, 2018). Briefly, cells were plated in desired amount and treated the next day with 2 mM thymidine (Sigma-Aldrich) for 23 h, afterwards cells were released in standard media without thymidine for 10h and second thymidine block (2 mM thymidine) was performed for 13.5 h. Next day, cells were released and collected at indicated time points depending on the experiment (Figure 3-figure supplement 1A, 8A). To enrich cells in PM phase, cells were treated with 100 ng/µl nocodazole (Sigma-Aldrich) after 3 h of release and collected after 12 additional hours. To block cells in G0/G1, cells were starved in media without serum for 16h.

Immunoprecipitations

For IP cells were collected and lysed in an appropriate volume of IP buffer [50 mM Tris-HCl, pH7.4; 50 mM KCl; 0.1% Triton X-100 supplemented freshly with protease inhibitor cocktail (Sigma-Aldrich)] for 30 min on ice after passing 3x through syringe (30G x 1/2", B. Braun Sterican). For SILAC samples, the lysate was incubated with 25 U benzonase HC nuclease (Sigma-Aldrich) at 37 °C for 30 min before IP. Afterwards, lysates were cleared by centrifugation at 20,000 x g for 30 min and protein amount was determined by standard Bradford assay (Biorad). For each reaction, 300-500 µg of protein were diluted in 250 µl IP buffer and incubated for 3h in head-to-toe agitation at 4°C with 0.5 µg of the specific antibody: rabbit polyclonal rabbit anti-CLUH [#NB100-93305 (1) and #NB100-93306 (2) from Novus Biologicals]; rabbit polyclonal anti-kinastin (#SAB1103031 from Sigma-Aldrich); rabbit polyclonal anti-astrin (#14726-1-AP from ProteinTech; #NB100-74638 from Novus Biologicals). As control antibodies, we used rabbit polyclonal anti-AFG3L1 (Koppen et al, 2007) (Figure 1A, B and Figure S1C) and rabbit polyclonal anti-FLAG (#F7425 from Sigma-Aldrich) (Figure 3, Figure S1B, D). 20 µl of prewashed magnetic Dynabeads Protein G (Invitrogen) were added per reaction and incubated for 1 h in head-to-toe agitation at 4°C. Afterwards, beads were washed five times with IP buffer. To elute kinastin, beads were incubated in 100 mM glycine, pH 2.3 for 20 min at 4°C. In the other cases, proteins were eluted in 30 µl 3x Laemmli buffer (20 mM Tris-HCl, pH 6.8, 2% SDS, 5% β-mercaptoethanol, 2.5% glycerol and 2.5% bromophenol blue) by vortexing for 1 min and boiling at 95°C for 5 min. Samples were stored at -20°C or run immediately on SDS-PAGE.

Sample preparation for mass spectrometry

For IP of CLUH followed by mass spectrometry of WT cells enriched in G2, experiments were carried out as described before using 400 µg lysate as input and elution was done with 30 µl SP3 lysis buffer (5% SDS in 1x PBS) by vortexing for 1 min and boiling at 95°C for 5 min.

Afterwards, proteins were reduced with 5 mM dithiothreitol for 30 min at 55°C and alkylated with 40 mM chloroacetamide at RT for 30 min in the dark. Next, samples were centrifuged at 20,000 x g for 10 min and supernatant was transferred to new tube and stored at -20°C before mass spectrometry was performed. For SILAC labelled samples, beads were resuspended in 50 µl of elution buffer 1 (2M urea, 50 mM triethylammoniumbicarbonate, 1 mM DTT, 5 ng/µl trypsin) and incubated at RT for 30 min while shaking. Beads were centrifuged and supernatant transferred to a new tube. Beads were washed twice with elution buffer 2 (2M urea, 50 mM triethylammoniumbicarbonate, 5 mM chloroacetamide) and centrifuged. The eluates were combined. Next, proteins were digested with lysyl endopeptidase (Wako Pure Chemical Industries) and trypsin (Sigma-Aldrich) with an enzyme:substrate ratio of 1:75 at 37 °C for 16 h. Next day, samples were acidified with formic acid to stop enzymatic digestion, purified with and loaded on StageTips as described before (Rappsilber et al, 2007).

HeLa WT, *SPAG5* and *KNSTRN* ind-KO cells were collected by scraping, pelleted and resuspended in appropriate amount of lysis buffer [50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EDTA, pH8; 1% IGEPAL CA-630; 0.25% sodium deoxycholate freshly supplemented with protease inhibitor cocktail (Sigma-Aldrich)]. Lysates were passed 3x through syringe (30G x 1/2", B. Braun Sterican) and incubated on ice for 30 min. After centrifugation for 30 min at 20,000 x g at 4°C, protein amounts were determined using standard Bradford assay (Biorad) and 30 µg of protein lysate were precipitated with acetone. Briefly, 4x volume of ice-cold acetone were added to lysates, incubated for 15 min at -80°C followed by 90 min incubation at -20°C and centrifugation for 15 min at 16,000 x g. Pellets were washed in ice-cold acetone, air-dried and resuspended in 50 µl of 8 M urea in 50 mM triethylammoniumbicarbonate including protease inhibitor cocktail (Roche). Afterwards proteins were reduced with 5 mM dithiothreitol for 1h at 25°C and alkylated with 40 mM chloroacetamide for 30 min in the dark. Next, proteins were digested with lysyl endopeptidase (Wako Pure Chemical Industries) with an enzyme:substrate ratio of 1:75 at 25°C for 4h. Samples were diluted with 50 mM

triethylammoniumbicarbonate to reach a final urea concentration of 2 M. Then proteins were digested with trypsin (Sigma-Aldrich) with an enzyme:substrate ratio of 1:75 and incubation at 25°C for 16 h. Next day, samples were acidified with formic acid to stop enzymatic digestion, purified with and loaded on StageTips as described before (Rappsilber et al, 2007). Samples were stored in dried StageTips at 4°C until mass spectrometry was performed.

Mass spectrometry of CLUH IP after SILAC

SILAC labelled samples were analyzed on a Q Exactive Plus Orbitrap (Thermo Scientific) mass spectrometer that was coupled to an EASY nLC (Thermo Scientific). Peptides were loaded with solvent A (0.1% formic acid in water) onto an in-house packed analytical column (50 cm x 75 µm I.D., filled with 2.7 µm Poroshell EC120 C18, Agilent). Peptides were chromatographically separated at a constant flow rate of 250 nL/min using the following gradient: 7-23% solvent B (0.1% formic acid in 80 % acetonitrile) within 35.0 min, 23-32% solvent B within 5.0 min, 32-85% solvent B within 5.0 min, followed by washing and column equilibration. The mass spectrometer was operated in data-dependent acquisition mode. The MS1 survey scan was acquired from 300-1750 m/z at a resolution of 70,000. The top 10 most abundant peptides were isolated within a 1.8 Th window and subjected to HCD fragmentation at a normalized collision energy of 27%. The AGC target was set to 5e5 charges, allowing a maximum injection time of 108 ms. Product ions were detected in the Orbitrap at a resolution of 35,000. Precursors were dynamically excluded for 20.0 s. All mass spectrometric raw data were processed with Maxquant (version 1.5.3.8) using default parameters. Briefly, MS2 spectra were searched against the Uniprot HUMANc_UP000005640.fasta (downloaded at: 26.08.2020) database, including a list of common contaminants. False discovery rates on protein and PSM level were estimated by the target-decoy approach to 1% (Protein FDR) and 1% (PSM FDR) respectively. The minimal peptide length was set to 7 amino acids and carbamidomethylation at cysteine residues was considered as a fixed modification. Oxidation (M) and Acetyl (Protein N-term)

were included as variable modifications. SILAC/dimethyl labeling quantification was used, and the re-quantify option was enabled.

Mass spectrometry of CLUH IP in synchronized cells

Immunoprecipitated proteins from cells synchronized in G2 were analyzed on a Q-Exactive Plus (Thermo Scientific) mass spectrometer that was coupled to an EASY nLC 1200 UPLC (Thermo Scientific). Peptides were loaded with solvent A (0.1% formic acid in water) onto an in-house packed analytical column (50 cm × 75 µm I.D., filled with 2.7 µm Poroshell EC120 C18, Agilent). Peptides were chromatographically separated at a constant flow rate of 250 nL/min using the following gradient: 3-5% solvent B (0.1% formic acid in 80 % acetonitrile) within 1 min, 5% - 30% solvent B (0.1% formic acid in 80 % acetonitrile) within 40 min, 30% -50% solvent B 8 min and 40% to 95% solvent B within 1 min, followed by washing with 95% solvent B for 10 min. The mass spectrometer was operated in data-dependent acquisition mode. The MS1 survey scan was acquired from 300 to 1750 m/z at a resolution of 70,000. The top 10 most abundant peptides were isolated within a 1.8 Th window and subjected to HCD fragmentation at a normalized collision energy of 27%. The AGC target was set to 5e5 charges, allowing a maximum injection time of 110 ms. Product ions were detected in the Orbitrap at a resolution of 35,000. Precursors were dynamically excluded for 10 s. All mass spectrometric raw data were processed with MaxQuant version 1.5.3.8 (Tyanova et al, 2016b) using default parameters. Briefly, MS2 spectra were searched against a canonical Uniprot human fasta database, which was modified by replacing the default entry for SPAG5 (Q96R06) by two separate entries representing (i) the N-terminal 125 amino acids and (ii) the C-terminal sequence from position 126 on. The MaxQuant default list was used to filter for common contaminants. False discovery rates on protein and PSM level were estimated by the target-decoy approach to 1% (Protein FDR) and 1% (PSM FDR) respectively. The minimal peptide length was set to 7 amino acids and carbamidomethylation at cysteine residues was considered

as a fixed modification. Oxidation (M) and Acetyl (Protein N-term) were included as variable modifications. The match-between runs option was restricted to replicates of the same condition. LFQ quantification was used with default settings. LFQ intensities were loaded into in Perseus version 1.6.1.1 (Tyanova et al, 2016a). Decoys and potential contaminants were removed and the dataset was filtered for at least 4 out of 4 values in at least one condition. Remaining missing values were imputed with random values from the left end of the intensity distribution using Perseus defaults. Two sample Student's T-test were calculated using permutation-based FDR estimation.

Mass spectrometry of *SPAG5* and *KNSTRN* ind-KO cells

For proteomics of HeLa WT ind, *SPAG5* and *KNSTRN* ind-KO cells, peptide digests were analyzed on a Q Exactive plus Orbitrap (Thermo Scientific) mass spectrometer that was coupled to an EASY nLC (Thermo Scientific). Samples were loaded onto an in-house packed analytical column (50 cm x 75 µm I.D., filled with 2.7 µm Poroshell EC120 C18, Agilent). Peptides were separated at a flow rate of 250 nL/min and the following gradient: 3-5% solvent B (0.1% formic acid in 80 % acetonitrile) within 1.0 min, 5-30% solvent B within 91.0 min, 30-50% solvent B within 17.0 min, 50-95% solvent B within 1.0 min, followed by washing with 95 % solvent B for 10 min. DDA runs for spectrum library generation were acquired from distinct pools of the sample groups and Hek293 cell digests fractionated high pH HPLC. MS1 survey scan were acquired at a resolution of 70,000. The top 10 most abundant peptides were isolated within a 2.0 Th window and subjected to HCD fragmentation with normalized collision energy of 27%. The AGC target was set to 5e5 charges, allowing a maximum injection time of 105 ms. Product ions were detected in the orbitrap at a resolution of 35,000. Precursors were dynamically excluded for 20.0 s. Sample runs were acquired in data-independent mode using 10 variable windows covering the mass range from m/z 450 to m/z 1200. MS1 scans were acquired at 140,000 resolution, maximum IT restricted to 120 ms and an AGC target set to 5e6 charges.

The settings for MS2 scans were 17,500 resolution, maximum IT restricted to 60 ms and AGC target set to 5e6 charges. The default charge state for the MS2 was set to 4. Stepped normalized collision energy was set to 23.5, 26 and 28.5. All spectra were acquired in profile mode. A hybrid spectrum library was generated in Spectronaut 13 (Bruderer et al, 2015) using DDA library runs, DIA sample runs and a canonical human sequence file (SwissProt, 20416 entries) downloaded from Uniprot. Spectronaut default settings were used for the analysis of the DIA runs. Protein identifications were filtered for q-values below 0.01 and normalized intensities were exported for subsequent statistical analysis in Perseus 1.6.1.1 (Tyanova et al, 2016b). Intensities were transformed to log2 values and the dataset was filtered for at least 4 out of 4 values in at least one condition. Remaining missing values were imputed with random values from the left end of the intensity distribution (with 0.3 sd, downshift 2 sd). Two sample Student's T-tests were calculated using permutation based FDR estimation.

Proteomics visualization and pathway analysis

Enriched proteins of IP experiment or proteomics results were visualized as volcano plots using Instant Clue software (Nolte et al, 2018) and pathway analysis was carried out using the EnrichR webtool with a cut off of $q \leq 0.05$ and $\log_2$ fold change ≥ 3 for the IP and a cut off of $q \leq 0.15$ and $p \leq 0.05$ for the proteomics analysis (Chen et al, 2013; Kuleshov et al, 2016; Xie et al, 2021).

Isolation of mitochondria

Cells were collected from confluent 15 cm plates with trypsinization, washed twice with PBS, and resuspended in an ice-cold mitochondria isolation buffer containing 20 mM HEPES, pH 7.6; 220 mM mannitol; 70 mM sucrose; 1 mM EDTA; 0.2% fatty acid-free bovine serum albumin (BSA). After 20 min of incubation on ice, cells were homogenized using the rotational engine homogenizer (Potter S, Sartorius; 30 strokes, 1200 rpm) followed by centrifugation at

850 $\times$ g. Next, mitochondria were pelleted at 8500 $\times$ g for 10 min at 4 °C, washed with BSA-
free buffer, and protein concentration was determined with Bradford reagent (Sigma-Aldrich).
For further analysis, mitochondria were subjected to blue native polyacrylamide gel
electrophoresis (BN-PAGE) followed by western blotting or determination of the in-
gel activity of respiratory complexes

Analysis of mitochondrial respiratory complexes with BN-PAGE

20 mg of mitochondria were lysed with digitonin (Calbiochem; 6.6 g/g protein) for 15 min on
ice with occasional vortexing and cleared from insoluble material for 20 min at 20,000 $\times$ g at 4
°C. Lysates were combined with Coomassie G-250 (0.25% final concentration). Mitochondrial
respiratory supercomplexes were resolved with BN-PAGE using the 4–16% NativePAGE
Novex Bis-Tris Mini Gels (Invitrogen) in a Bis-Tris/Tricine buffering system with cathode
buffer initially supplemented with 0.02% G-250 followed by the 0.002% G-250. For complex
I in-gel activity, gels were incubated at RT in a buffer containing 0.01 mg/mL NADH and 2.5
mg/mL nitroterrazolium blue in 5 mM Tris-HCl, pH 7.4.

Cell lysis and western blot

Cell pellets were lysed in appropriate amount of lysis buffer [50 mM Tris-HCl, pH 7.4; 150
mM NaCl; 1 mM EDTA, pH8; 1% IGEPAL CA-630; 0.25% sodium deoxycholate freshly
supplemented with protease inhibitor cocktail (Sigma-Aldrich)] and protein amounts were
determined by standard Bradford assay (Biorad). Desired protein amounts were mixed with
appropriate volume of 3x loading buffer (20 mM Tris-HCl, pH6.8; 2% SDS; 5% β -
mercaptoethanol; 2.5% glycerol and 2.5% bromophenol blue), boiled for 5 min at 95°C and
loaded on SDS polyacrylamide gels. Proteins were separated by SDS PAGE and blotted on
polyvinylidene fluoride (PVDF) membranes using wet transfer. After BN-PAGE, separated
mitochondrial complexes were transferred on PVDF membranes using the wet transfer sodium

lauryl sulfate (SDS)-free and methanol-free system. The following primary antibodies were used for western blotting: rabbit polyclonal anti-CLUH antibodies [detecting human CLUH; #NB100-93305 (1), #NB100-93306 (2)], rabbit polyclonal anti-RPS6 (#NB100-1595), rabbit polyclonal anti-RPL7 (#NB100-2269) antibodies from Novus Biologicals; rabbit polyclonal anti-astrin (#14726-1-AP) antibody from ProteinTech; rabbit polyclonal anti-FLAG (#F7425) and mouse monoclonal anti-FLAG (#F3165) antibodies from Sigma-Aldrich; mouse monoclonal pan-actin (#MAB1501) and anti-GAPDH (#MAB374) antibodies from EMD Millipore; rabbit polyclonal anti-CLUH antibody (detecting murine CLUH; #ARP70642_P050) from Aviva; rabbit polyclonal anti-kinastrin (#ab122769) and rabbit polyclonal pH3-Ser10 (#ab5176) antibodies from Abcam; mouse monoclonal anti-SDHA (#459200), anti-NDUFA9 (#459100) and anti-UQCRC1 (#459140) from Molecular probes; rabbit polyclonal pRB1-Ser807/811 (#9308), rabbit monoclonal pCDK1-Tyr15 (#4539), mouse monoclonal anti-cyclin D3 (#2936) and rabbit polyclonal pRPS6-Ser235/236 (#2211) antibodies from Cell Signaling and mouse monoclonal anti-CDK1 (#sc-54) antibody from Santa Cruz Biotechnologies.

Sample collection to measure anionic metabolites, amino acids and polyamines

WT, *SPAG5* and *KNSTRN* ind-KO cells were induced as described before and 1,000,000 cells were plated in 6 well plates the day before the extraction. Next day, the cells were either collected immediately (basal condition) or starved for 8h in HBSS media (#14025092, Gibco) in absence of doxycycline. Cells were washed twice with buffer containing 75 mM ammonium carbonate (pH7.4) and metabolites were extracted with cold (-20°C) extraction solvent (40:40:20 acetonitrile:methanol:water) and incubation for 10 min at -20°C. Supernatant was collected and extraction was repeated. Afterwards, cells were scraped on ice and combined with the supernatant of the previous step. Samples were immediately dried in a speed vac concentrator and dried pellets were kept at -80°C until mass spectrometry was performed.

Anion-Exchange Chromatography Mass Spectrometry (AEX-MS) for the analysis of anionic metabolites

Extracted metabolites were re-suspended in 150 µl of Optima LC/MS grade water (Thermo Fisher Scientific), of which 100 µl were transferred to polypropylene autosampler vials (Chromatography Accessories Trott, Germany) before AEX MS analysis. The samples were analysed using a Dionex ionchromatography system (Integrion, Thermo Fisher Scientific) as described previously (Schwaiger et al, 2017). In brief, 5 µL of polar metabolite extract were injected in push partial mode using an overfill factor of 3, onto a Dionex IonPac AS11-HC column (2 mm × 250 mm, 4 µm particle size, Thermo Fisher Scientific) equipped with a Dionex IonPac AG11-HC guard column (2 mm × 50 mm, 4 µm, Thermo Fisher Scientific). The column temperature was held at 30°C, while the auto sampler was set to 6°C. A potassium hydroxide gradient was generated using a potassium hydroxide cartridge (Eluent Generator, Thermo Scientific), which was supplied with deionized water. The metabolite separation was carried at a flow rate of 380 µL/min, applying the following gradient conditions: 0-3 min, 10 mM KOH; 3-12 min, 10-50 mM KOH; 12-19 min, 50-100 mM KOH, 19-21 min, 100 mM KOH, 21-22 min, 100-10 mM KOH. The column was re-equilibrated at 10 mM for 8 min. For the analysis of metabolic pool sizes the eluting compounds were detected in negative ion mode $[M-H]^-$ using multiple reaction monitoring (MRM) mode with the following settings: Capillary voltage 2.7 kV, desolvation temperature 550°C, desolvation gas flow 800 l/h, collision cell gas flow 0.15 mL/min. The detailed quantitative and qualitative transitions and electronic settings for the analyzed metabolites are summarized in Supplementary Table 4. The MS data analysis was performed using the TargetLynx Software (Version 4.1, Waters). For data analysis the area of the quantitative transition of each compound was extracted and integrated using a retention time (RT) tolerance of <0.1 min as compared to the independently measured reference compounds. Areas of the cellular pool sizes were normalized to the internal standards (citric acid D4), which

were added to the extraction buffer, followed by a normalization to the protein content of the analyzed sample. One sample of *CLUH* KO and one of *SPAG5* ind-KO cells upon HBSS starvation has been classified as outlier and removed from analysis. Samples were classified as outliers due to PCA plot and tremendous drift of measured values from other samples.

LC-MS analysis of cellular pool sizes of amino acids and polyamines

For amino acid analysis, the benzoylchlorid derivatization method (Wong et al, 2016) was used. In brief, 20 µl of the polar phase of each sample, were mixed with 10 µl of 100 mM sodium carbonate (Sigma-Aldrich) followed by the addition of 10 µl 2% benzoylchloride (Sigma-Aldrich) in acetonitrile (VWR). Samples were analyzed using an Acquity iClass UPLC (Waters) connected to a Q-Exactive HF (Thermo Fisher Scientific). For analysis, 1 µl of the derivatized sample was injected onto a 100 x 1.0 mm HSS T3 column, packed with 1.8 µm particles (Waters). The flow rate was 100 µL/min and the buffer system consisted of buffer A (10 mM ammonium formate, 0.15% formic acid in water) and buffer B (acetonitrile). The gradient was: 0% B at 0 min; 0-15% B 0-0.1 min; 15-17% B 0.1-0.5 min; 17-55% B 0.5-14 min; 55-70% B 14-14.5 min; 70-100% B 14.5-18 min; 100% B 18-19 min; 100-0% B 19-19.1 min, 19.1-28 min 0% B. The mass spectrometer was operating in positive ionization mode monitoring and the mass range was set to m/z 50-750. The heated ESI source settings of the mass spectrometer were: Spray voltage 3.5kV, capillary temperature 275°C, sheath gas flow 40 AU and aux gas flow 20 AU at a temperature of 300°C. The S-lens was set to 60 AU. Data analysis was performed using the TraceFinder software (Version 4.1, Thermo Fisher Scientific). Identity of each compound was validated by authentic reference compounds, which were injected and analyzed independently. Extracted ion chromatograms (XIC) were extracted as [M + H]⁺ ions with a mass accuracy (<5 ppm). Areas of the cellular pool sizes of the analyzed amines were normalized to their corresponding ¹³C¹⁵N internal standard or, if no corresponding ¹³C¹⁵N compound was present, they were normalized to the ¹³C¹⁵N leucine. Following the

normalization to the internal standard the values were normalized to the protein content of the analyzed sample.

Measurement of RNA stability

To measure mRNA stability, Click-iT Nascent RNA Capture Kit (Invitrogen) was used as described before (Schatton et al., 2017). Briefly, 500,000 cells were seeded on 3.5 cm dishes. The following day, endogenous RNA was labeled with 0.2 mM 5-ethynyl uridine (EU) for 24h and collected either immediately (0h time point) or after 8h incubation with media w/o EU with Trizol reagent (Invitrogen). Total RNA was isolated according to the instructions of the Trizol reagent manual and 3 µg RNA were biotinylated with biotin-azide using Click-iT chemistry reaction. Afterwards, RNA was precipitated with glycogen, 7.5 M ammonium acetate and 100% ice cold ethanol for 16h and centrifugation at 13,000 x g for 20 min at 4°C. RNA was washed twice with 70% ethanol, air-dried and resuspended in distilled H₂O. 1.5 µg RNA were incubated with prewashed Dynabeads MyOne Streptavidin T1 beads (Invitrogen) for 30 min in presence of RNaseOUT (Invitrogen). Afterwards beads were washed several times and RNA bound on beads was retrotranscribed with SuperScript VILO cDNA synthesis kit (Invitrogen) according to the manual. cDNA was stored at -20°C until qRT-PCR was performed. mRNA half-lives were calculated as described before (Schatton et al, 2017).

RNA isolation, cDNA synthesis, DNA isolation and quantitative real-time PCR

RNA was isolated with Trizol reagent (Invitrogen) according to the manual. 2 µg of total RNA were retro-transcribed using the SuperScript First-Strand Synthesis System (Invitrogen) with random hexamer primers according to the instructions of the manual. To isolate genomic DNA, cells were lysed with digestion buffer [100 mM NaCl; 10 mM Tris-HCl, pH8; 25 mM EDTA, pH8; 0.5% SDS supplemented freshly with 0.1 mg/mL proteinase K (Roche)] at 55°C for 16h. DNA was isolated with standard phenol/chloroform purification followed by ethanol

precipitation. For mtDNA quantification, 20 ng genomic DNA were used per reaction. SYBR green master mix (Applied Biosystems) was used for quantitative real-time PCR using either StepOne Plus Real-Time PCR system or Quant Studio 12K Flex Real-Time PCR System thermocycler (Applied Biosystems). For each reaction technical duplicates and at least three biological replicates per experiment were performed. *GAPDH* or *RPL13* were used for normalization and fold enrichment was calculated with the formula: $2^{(-\Delta\Delta Ct)}$. The following primers were used for amplification: *SPAG5* forward: 5'-CATCTCACAGTGGGATAACTAATAAAC-3'; *SPAG5* reverse: 5'-CAGGGATAGGTGAAGCAAGGATA-3'; *GAPDH* forward: 5'-AATCCCATCACCATCTTCCA-3'; *GAPDH* reverse: 5'-TGGACTCCACGACGTACTCA-3'; *RPL13* forward: 5'-CGGACCGTGCGAGGTAT-3'; *RPL13* reverse: 5'-CACCATCCGCTTTTCTTGTC-3'; *MT-TL1* forward: 5'-CACCCAAGAACAGGGTTTGT-3'; *MT-TL1* reverse: 5'-TGGCCATGGGTATGTTGTTA-3'; *B2M* forward: 5'-TGCTGTCTCCATGTTTGATGTATCT-3'; *B2M* reverse: 5'-TCTCTGCTCCCCACCTCTAAGT-3'.

Immunofluorescence and transmission electron microscopy

Cells were seeded in an appropriate amount on coverslips the day before. Next day, cells were washed twice with 1x PBS and fixed for 15 min either with 4% PFA/PBS (pH7.4) or with ice-cold 100% methanol at RT or -20°C, respectively, depending on the primary antibody and as indicated in the figure legends. Afterwards, cells were permeabilized with 0.2% Triton X-100 in 1x PBS for 10 min and blocked in 10% pig or goat serum for 10 min. Then coverslips were stained with primary antibodies diluted in 1% pig or goat serum in 1x PBS for 2h at RT or for 16h at 4°C. The following primary antibodies were used: rabbit polyclonal anti-CLUH antibody (1:1000, #NB100-93306, Novus Biologicals), mouse monoclonal anti-FLAG antibody (1:1000, #F3165, Sigma-Aldrich), mouse monoclonal anti-vinculin antibody (1:500, #MAB3574, EMD

Millipore), mouse monoclonal anti-TOMM20 antibody (1:1000, #sc-17764, Santa Cruz Biotechnologies), mouse monoclonal anti- γ -tubulin antibody (1:1000, #T6557, Sigma-Aldrich) and rabbit polyclonal anti-FLAG antibody (1:1000, #F7425, Sigma-Aldrich). Afterwards, coverslips were washed three times in 1x PBS for 5 min and incubated with secondary antibodies [donkey anti-rabbit Alexa594 (1:1000, #A21207, Invitrogen) and goat anti-mouse Alexa488 (1:1000, #11029, Invitrogen)] diluted in 1x PBS including 1% pig or goat serum for 1h at RT. Then coverslips were washed 3x in 1x PBS (the first washing including DAPI DNA dye) and mounted with Fluorsave reagent (Calibiochem). Transmission electron microscopy on cells was performed as previously described (Gao et al, 2014).

Microscopy and image analysis

Immunofluorescence images were acquired with a spinning-disk confocal microscope (UltraVIEW VoX, PerkinElmer) using a 60 $\times$ objective. Images represent a single plane and were deconvoluted using ImageJ (NIH) and brightness was adjusted equally in the entire images. Specificity of the anti-CLUH antibody has been proven before (Pla-Martin et al, 2020). For CLUH-granule quantification, at least 160 cells have been analyzed per genotype per experiment and cells with CLUH-granules were counted manually with the experimentator blinded for the genotype. For mitochondrial morphology assessment, a half-automated macro for ImageJ (Mitomorph) has been employed (Yim et al, 2020). At least 66 (basal) or 44 (galactose) cells per genotype per experiment were analyzed. Micrographs were acquired on a Jeol Jem2100Plus electron microscope operating at a voltage of 120 V using a GATAN OneView camera.

Propidium iodide staining and flow cytometry

Cells were synchronized as described before (Figure 8A), collected by trypsinization and pelleting, washed once with 1x PBS, fixed in ice-cold 70% ethanol in 1x PBS and stored at -

20°C for at least 16h. Fixed cells were pelleted at 2000 rpm for 10 min, washed once with 1x PBS and pelleted again at 2000 rpm for 5 min. Pellets were resuspended in 500 µl 1x PBS containing 0.25% Triton X-100, 100 µg/mL RNase A (#1007885, Qiagen) and 50 µg/mL PI (#P4864, Sigma-Aldrich) and incubated at least 30 min at RT before measured by flow cytometry. BD LSR Fortessa (BD Biosciences) was used with BD FACS Diva software at low flow rate using PE laser (561 nm excitation; 586/15 nm detection). At least 15,000 events were measured per sample. Flowing Software version 2.5.1 (developed by Perttu Terho, Turku Centre for Biotechnology, University of Turku, Finland) was used for analysis.

Statistics

Sample size has been determined by previous experience with similar analysis. Replicates are always biological independent experiments. Data are shown as mean ± SEM or ± SD as indicated in respective figure legends. To compare two groups, paired or unpaired Student's t-test was performed as indicated in the figure legends. To compare multiple groups, one-way ANOVA with post hoc Tukey's multiple comparison test was performed. To compare data sets including two variances, two-way ANOVA with post hoc Tukey's multiple comparison test was employed. Statistical significance was calculated using GraphPad Prism software. A P value < 0.05 was considered as significant. Statistical methods for proteomics analysis are described in the corresponding method section.

ACKNOWLEDGMENTS

We are grateful to Guy Lenaers for providing *CLUH* knock-out HeLa cells, and to Iain Cheeseman for sharing the *SPAG5* and *KNSTRN* ind-KO cell lines. We thank the CECAD imaging and proteomics facilities for excellent technical assistance, and members of the Rugarli laboratory for constructive discussions. This work was funded by the Deutsche Forschungsgemeinschaft (Project numbers 269925409 and 411422114-GRK 2550) to E.I.R.

COMPETING INTERESTS

The authors declare no competing interests.

REFERENCES

- Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT (2016) SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. *Lancet Oncol* **17**: 1004-1018
- Ahn E, Kumar P, Mukha D, Tzur A, Shlomi T (2017) Temporal fluxomics reveals oscillations in TCA cycle flux throughout the mammalian cell cycle. *Molecular Systems Biology* **13**: 953
- Bertucci F, Viens P, Birnbaum D (2016) SPAG5: the ultimate marker of proliferation in early breast cancer? *Lancet Oncol* **17**: 863-865
- Bruderer R, Bernhardt OM, Gandhi T, Miladinović SM, Cheng LY, Messner S, Ehrenberger T, Zanotelli V, Butscheid Y, Escher C, Vitek O, Rinner O, Reiter L (2015) Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. *Mol Cell Proteomics* **14**: 1400-1410
- Buchakjian MR, Kornbluth S (2010) The engine driving the ship: metabolic steering of cell proliferation and death. *Nat Rev Mol Cell Bio* **11**: 715-727
- Chang MS, Huang CJ, Chen ML, Chen ST, Fan CC, Chu JM, Lin WC, Yang YC (2001) Cloning and characterization of hMAP126, a new member of mitotic spindle-associated proteins. *Biochem Biophys Res Commun* **287**: 116-121
- Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC bioinformatics* **14**: 128

- 1038
- 1039 Cheng TS, Hsiao YL, Lin CC, Hsu CM, Chang MS, Lee CI, Yu RC, Huang CY, Howng SL, Hong YR
- 1040 (2007) hNinein is required for targeting spindle-associated protein Astrin to the centrosome during the
- 1041 S and G2 phases. *Exp Cell Res* **313**: 1710-1721
- 1042
- 1043 Cheng TS, Hsiao YL, Lin CC, Yu CT, Hsu CM, Chang MS, Lee CI, Huang CY, Howng SL, Hong YR
- 1044 (2008) Glycogen synthase kinase 3beta interacts with and phosphorylates the spindle-associated protein
- 1045 astrin. *J Biol Chem* **283**: 2454-2464
- 1046
- 1047 Chiu SC, Chen JM, Wei TY, Cheng TS, Wang YH, Ku CF, Lian CH, Liu CC, Kuo YC, Yu CT (2014)
- 1048 The mitosis-regulating and protein-protein interaction activities of astrin are controlled by aurora-A-
- 1049 induced phosphorylation. *Am J Physiol Cell Physiol* **307**: C466-478
- 1050
- 1051 Chung HJ, Park JE, Lee NS, Kim H, Jang CY (2016) Phosphorylation of Astrin Regulates Its
- 1052 Kinetochores Function. *J Biol Chem* **291**: 17579-17592
- 1053
- 1054 Cuyàs E, Corominas-Faja B, Joven J, Menendez JA (2014) Cell cycle regulation by the nutrient-sensing
- 1055 mammalian target of rapamycin (mTOR) pathway. *Methods Mol Biol* **1170**: 113-144
- 1056
- 1057 Dai LY, Zhao TY, Bisteau X, Sun WD, Prabhu N, Lim YT, Sobota RM, Kaldis P, Nordlund P (2018)
- 1058 Modulation of Protein-Interaction States through the Cell Cycle. *Cell* **173**: 1481-+
- 1059
- 1060 DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: Metabolic
- 1061 reprogramming fuels cell growth and proliferation. *Cell Metab* **7**: 11-20
- 1062
- 1063 Dunsch AK, Linnane E, Barr FA, Gruneberg U (2011) The astrin-kinastrin/SKAP complex localizes to
- 1064 microtubule plus ends and facilitates chromosome alignment. *The Journal of cell biology* **192**: 959-968
- 1065
- 1066 Dutchak PA, Estill-Terpack SJ, Plec AA, Zhao X, Yang C, Chen J, Ko B, Deberardinis RJ, Yu Y, Tu
- 1067 BP (2018) Loss of a Negative Regulator of mTORC1 Induces Aerobic Glycolysis and Altered Fiber
- 1068 Composition in Skeletal Muscle. *Cell Rep* **23**: 1907-1914
- 1069
- 1070 Friese A, Faesen AC, Huis in 't Veld PJ, Fischbock J, Prumbaum D, Petrovic A, Raunser S, Herzog F,
- 1071 Musacchio A (2016) Molecular requirements for the inter-subunit interaction and kinetochores
- 1072 recruitment of SKAP and Astrin. *Nat Commun* **7**: 11407
- 1073
- 1074 Gao J, Schatton D, Martinelli P, Hansen H, Pla-Martin D, Barth E, Becker C, Altmueller J, Frommolt
- 1075 P, Sardiello M, Rugarli EI (2014) CLUH regulates mitochondrial biogenesis by binding mRNAs of
- 1076 nuclear-encoded mitochondrial proteins. *J Cell Biol* **207**: 213-223
- 1077
- 1078 Geraghty Z, Barnard C, Uluocak P, Gruneberg U (2021) The association of Plk1 with the astrin-
- 1079 kinastrin complex promotes formation and maintenance of a metaphase plate. *J Cell Sci* **134**
- 1080
- 1081 Gholkar AA, Senese S, Lo Y-C, Vides E, Contreras E, Hodara E, Capri J, Whitelegge JP, Torres JZ
- 1082 (2016) The X-Linked-Intellectual-Disability-Associated Ubiquitin Ligase Mid2 Interacts with Astrin
- 1083 and Regulates Astrin Levels to Promote Cell Division. *Cell Rep* **14**: 180-188
- 1084

- 1085 Gruber J, Harborth J, Schnabel J, Weber K, Hatzfeld M (2002) The mitotic-spindle-associated protein
1086 astrin is essential for progression through mitosis. *J Cell Sci* **115**: 4053-4059
- 1087
- 1088 Halim VA, Alvarez-Fernandez M, Xu YJ, Aprelia M, van den Toorn HWP, Heck AJR, Mohammed S,
1089 Medema RH (2013) Comparative Phosphoproteomic Analysis of Checkpoint Recovery Identifies New
1090 Regulators of the DNA Damage Response. *Sci Signal* **6**
- 1091
- 1092 Halim VA, Garcia-Santisteban I, Warmerdam DO, van den Broek W, Heck AJR, Mohammed S,
1093 Medema RH (2018) Doxorubicin-induced DNA Damage Causes Extensive Ubiquitination of
1094 Ribosomal Proteins Associated with a Decrease in Protein Translation. *Molecular & Cellular*
1095 *Proteomics* **17**: 2297-2308
- 1096
- 1097 Harbauer AB, Opalinska M, Gerbeth C, Herman JS, Rao S, Schonfisch B, Guiard B, Schmidt O, Pfanner
1098 N, Meisinger C (2014) Cell cycle-dependent regulation of mitochondrial preprotein translocase. *Science*
1099 **346**: 1109-1113
- 1100
- 1101 Kern DM, Monda JK, Su KC, Wilson-Kubalek EM, Cheeseman IM (2017) Astrin-SKAP complex
1102 reconstitution reveals its kinetochore interaction with microtubule-bound Ndc80. *Elife* **6**
- 1103
- 1104 Kern DM, Nicholls PK, Page DC, Cheeseman IM (2016) A mitotic SKAP isoform regulates spindle
1105 positioning at astral microtubule plus ends. *J Cell Biol* **213**: 315-328
- 1106
- 1107 Khan NA, Nikkanen J, Yatsuga S, Jackson C, Wang L, Pradhan S, Kivela R, Pessia A, Velagapudi V,
1108 Suomalainen A (2017) mTORC1 Regulates Mitochondrial Integrated Stress Response and
1109 Mitochondrial Myopathy Progression. *Cell Metab* **26**: 419-428 e415
- 1110
- 1111 Kodani A, Yu TW, Johnson JR, Jayaraman D, Johnson TL, Al-Gazali L, Sztriha L, Partlow JN, Kim H,
1112 Krup AL, Dammermann A, Krogan NJ, Walsh CA, Reiter JF (2015) Centriolar satellites assemble
1113 centrosomal microcephaly proteins to recruit CDK2 and promote centriole duplication. *Elife* **4**
- 1114
- 1115 Koppen M, Metodiev MD, Casari G, Rugarli EI, Langer T (2007) Variable and Tissue-Specific Subunit
1116 Composition of Mitochondrial m-AAA Protease Complexes Linked to Hereditary Spastic Paraplegia.
1117 *Mol Cell Biol* **27**: 758-767
- 1118
- 1119 Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL,
1120 Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A (2016)
1121 Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res* **44**:
1122 W90-97
- 1123
- 1124 Leal-Esteban LC, Fajas L (2020) Cell cycle regulators in cancer cell metabolism. *Bba-Mol Basis Dis*
1125 **1866**
- 1126
- 1127 Lee IH, Finkel T (2013) Metabolic regulation of the cell cycle. *Curr Opin Cell Biol* **25**: 724-729
- 1128
- 1129 Li M, Li A, Zhou S, Lv H, Yang W (2019) SPAG5 upregulation contributes to enhanced c-MYC
1130 transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
1131 *Journal of hematology & oncology* **12**: 14
- 1132

MacVicar T, Ohba Y, Nolte H, Mayer FC, Tatsuta T, Sprenger H-G, Lindner B, Zhao Y, Li J, Bruns C, Krüger M, Habich M, Riemer J, Schwarzer R, Pasparakis M, Henschke S, Brüning JC, Zamboni N, Langer T (2019) Lipid signalling drives proteolytic rewiring of mitochondria by YME1L. *Nature* **575**: 361-365

Mandal S, Guptan P, Owusu-Ansah E, Banerjee U (2005) Mitochondrial Regulation of Cell Cycle Progression during Development as Revealed by the tenured Mutation in Drosophila. *Dev Cell* **9**: 843-854

Manning AL, Bakhoun SF, Maffini S, Correia-Melo C, Maiato H, Compton DA (2010) CLASP1, astrin and Kif2b form a molecular switch that regulates kinetochore-microtubule dynamics to promote mitotic progression and fidelity. *The EMBO journal* **29**: 3531-3543

McKinley KL, Cheeseman IM (2017) Large-Scale Analysis of CRISPR/Cas9 Cell-Cycle Knockouts Reveals the Diversity of p53-Dependent Responses to Cell-Cycle Defects. *Dev Cell* **40**: 405-420

Mitra K, Wunder C, Roysam B, Lin G, Lippincott-Schwartz J (2009) A hyperfused mitochondrial state achieved at G(1)-S regulates cyclin E buildup and entry into S phase. *Proc Natl Acad Sci U S A* **106**: 11960-11965

Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J, Topisirovic I, Sonenberg N (2013) mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation. *Cell Metab* **18**: 698-711

Morita M, Prudent J, Basu K, Goyon V, Katsumura S, Hulea L, Pearl D, Siddiqui N, Strack S, McGuirk S, St-Pierre J, Larsson O, Topisirovic I, Vali H, McBride HM, Bergeron JJ, Sonenberg N (2017) mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1. *Mol Cell* **67**: 922-935 e925

Morris DR, Geballe AP (2000) Upstream open reading frames as regulators of mRNA translation. *Mol Cell Biol* **20**: 8635-8642

Nolte H, MacVicar TD, Tellkamp F, Kruger M (2018) Instant Clue: A Software Suite for Interactive Data Visualization and Analysis. *Sci Rep* **8**

Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. *Sci Signal* **3**: ra3

Pla-Martin D, Schatton D, Wiederstein JL, Marx MC, Khiati S, Kruger M, Rugarli EI (2020) CLUH granules coordinate translation of mitochondrial proteins with mTORC1 signaling and mitophagy. *EMBO J* **39**: e102731

Rabanal-Ruiz Y, Byron A, Wirth A, Madsen R, Sedlackova L, Hewitt G, Nelson G, Stingle J, Wills JC, Zhang T, Zeug A, Fassler R, Vanhaesebroeck B, Maddocks ODK, Ponimaskin E, Carroll B, Korolchuk VI (2021) mTORC1 activity is supported by spatial association with focal adhesions. *J Cell Biol* **220**

- 1181 Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification, enrichment, pre-fractionation
1182 and storage of peptides for proteomics using StageTips. *Nat Protocols* **2**: 1896-1906
- 1183
- 1184 Salazar-Roa M, Malumbres M (2017) Fueling the Cell Division Cycle. *Trends Cell Biol* **27**: 69-81
- 1185
- 1186 Schatton D, Pla-Martin D, Marx MC, Hansen H, Mourier A, Nemazanyy I, Pessia A, Zentis P, Corona
1187 T, Kondylis V, Barth E, Schauss AC, Velagapudi V, Rugarli EI (2017) CLUH regulates mitochondrial
1188 metabolism by controlling translation and decay of target mRNAs. *J Cell Biol* **216**: 675-693
- 1189
- 1190 Schatton D, Rugarli EI (2018) A concert of RNA-binding proteins coordinates mitochondrial function.
1191 *Crit Rev Biochem Mol Biol* **53**: 652-666
- 1192
- 1193 Schmidt JC, Kiyomitsu T, Hori T, Backer CB, Fukagawa T, Cheeseman IM (2010) Aurora B kinase
1194 controls the targeting of the Astrin-SKAP complex to bioriented kinetochores. *J Cell Biol* **191**: 269-280
- 1195
- 1196 Schwaiger M, Rampler E, Hermann G, Miklos W, Berger W, Koellensperger G (2017) Anion-Exchange
1197 Chromatography Coupled to High-Resolution Mass Spectrometry: A Powerful Tool for Merging
1198 Targeted and Non targeted Metabolomics. *Anal Chem* **89**: 7667-7674
- 1199
- 1200 Thedieck K, Holzwarth B, Prentzell MT, Boehlke C, Klasener K, Ruf S, Sonntag AG, Maerz L,
1201 Grellscheid SN, Kremmer E, Nitschke R, Kuehn EW, Jonker JW, Groen AK, Reth M, Hall MN,
1202 Baumeister R (2013) Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer
1203 cells. *Cell* **154**: 859-874
- 1204
- 1205 Thein KH, Kleylein-Sohn J, Nigg EA, Gruneberg U (2007) Astrin is required for the maintenance of
1206 sister chromatid cohesion and centrosome integrity. *J Cell Biol* **178**: 345-354
- 1207
- 1208 Tyanova S, Temu T, Cox J (2016a) The MaxQuant computational platform for mass spectrometry-based
1209 shotgun proteomics. *Nat Protocols* **11**: 2301-2319
- 1210
- 1211 Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016b) The Perseus
1212 computational platform for comprehensive analysis of (prote)omics data. *Nat Meth* **13**: 731-740
- 1213
- 1214 Wakim J, Goudenege D, Perrot R, Gueguen N, Desquirit-Dumas V, Chao de la Barca JM, Dalla Rosa
1215 I, Manero F, Le Mao M, Chupin S, Chevrollier A, Procaccio V, Bonneau D, Logan DC, Reynier P,
1216 Lenaers G, Khiati S (2017) CLUH couples mitochondrial distribution to the energetic and metabolic
1217 status. *J Cell Sci* **130**: 1940-1951
- 1218
- 1219 Wang ZQ, Fan M, Candas D, Zhang TQ, Qin LL, Eldridge A, Wachsmann-Hogiu S, Ahmed KM,
1220 Chromy BA, Nantajit D, Duru N, He FC, Chen M, Finkel T, Weinstein LS, Li JJ (2014) Cyclin B1/Cdk1
1221 Coordinates Mitochondrial Respiration for Cell-Cycle G2/M Progression. *Dev Cell* **29**: 217-232
- 1222
- 1223 Wong JMT, Malec PA, Mabrouk OS, Ro J, Dus M, Kennedy RT (2016) Benzoyl chloride derivatization
1224 with liquid chromatography-mass spectrometry for targeted metabolomics of neurochemicals in
1225 biological samples. *J Chromatogr A* **1446**: 78-90
- 1226

1227 Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, Lachmann A, Wojciechowicz
1228 ML, Kropiwnicki E, Jagodnik KM, Jeon M, Ma'ayan A (2021) Gene Set Knowledge Discovery with
1229 Enrichr. *Current Protocols* **1**: e90

1230
1231 Yim A, Koti P, Bonnard A, Marchiano F, Dürrbaum M, Garcia-Perez C, Villaveces J, Gamal S, Cardone
1232 G, Perocchi F, Storchova Z, Habermann BH (2020) mitoXplorer, a visual data mining platform to
1233 systematically analyze and visualize mitochondrial expression dynamics and mutations. *Nucleic Acids*
1234 *Res* **48**: 605-632

1235
1236 Ying Z, Yang J, Li W, Wang X, Zhu Z, Jiang W, Li C, Sha O (2020) Astrin: A Key Player in Mitosis
1237 and Cancer. *Front Cell Dev Biol* **8**: 866-866

1238
1239 Young SK, Wek RC (2016) Upstream Open Reading Frames Differentially Regulate Gene-specific
1240 Translation in the Integrated Stress Response. *J Biol Chem* **291**: 16927-16935

1241
1242 Yuan LJ, Li JD, Zhang L, Wang JH, Wan T, Zhou Y, Tu H, Yun JP, Luo RZ, Jia WH, Zheng M (2014)
1243 SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol
1244 treatment via the mTOR signaling pathway. *Cell Death Dis* **5**: e1247

1245
1246 Zhou H, Wang SC, Ma JM, Yu LQ, Jing JS (2018) Sperm-Associated Antigen 5 Expression Is Increased
1247 in Hepatocellular Carcinoma and Indicates Poor Prognosis. *Medical science monitor : international*
1248 *medical journal of experimental and clinical research* **24**: 6021-6028

1249
1250

1251
1252

SUPPLEMENTARY FIGURES

Figure 1-figure supplement 1. CLUH interacts with full length astrin independently of kinastrin.

(A) Scheme of C-terminally FLAG-tagged astrin constructs used for overexpression in this study. Positions of ATGs and mutagenized ATGs are indicated. (B) Western blot of IP of endogenous astrin using antibodies binding N-terminal or C-terminal epitopes of astrin in HeLa cells. (C) Western blots of reciprocal co-IPs in HEK293T cells stably overexpressing FLAG-kinastrin or empty FLAG using antibodies against endogenous CLUH, astrin and overexpressed kinastrin. GAPDH was used as loading control for input samples. (D) Western blots of reciprocal co-IPs of endogenous CLUH and astrin in WT, *SPAG5* and *KNSTRN* ind-KO HeLa cells.

Figure 2- figure supplement 1. Astrin is unstable in *Cluh* KO MEFs.

(A) Western blots of CHX chase in WT and *Cluh* KO MEFs treated for indicated time points. Pan-actin staining was used as loading control. (B) Quantification of CHX chase western blots as shown in A (n=3 independent experiments). Two-way ANOVA with post hoc Tukey's multiple comparison test was performed with $P \leq 0.05$: *; $P \leq 0.01$: **; $P \leq 0.001$: ***. Genotype x time interaction significance is also shown. Graphs show mean $\pm$ SEM.

Figure 3- figure supplement 1. Controls of effective synchronization of IP samples.

(A) Synchronization protocol used for IP experiments. Cells enriched in G1/S and G2 were collected after 1 h and 6 h after release of the 2nd thymidine block, respectively. Cells enriched in prometaphase (PM) were treated with nocodazole (noc) after 3 h of release and collected after additional 12 h. (B, C) PI intensity profiles (B) and cell cycle distribution analysis (C) of non-synchronized (ns) or G2-enriched WT cells used for IP followed by mass spectrometry (n=4 independent replicates).

Figure 5-figure supplement 1. *SPAG5* and *KNSTRN* ind KO HeLa cells show normal mitochondrial morphology.

(A, B) Western blots of induction time course in WT and *SPAG5* (A) or *KNSTRN* (B) ind-KO HeLa cells. Cells were treated with doxycycline for indicated time points. +/- means that cells were treated with doxycycline for 72 h and not treated for the remaining 24 h. Pan-actin was used as loading control. (C) Quantification of mitochondrial morphology of experiments shown in Figure 5A (n=3 independent experiments; in total the following number of cells have been analyzed: basal: WT ind: 248, *SPAG5* ind KO: 244, *KNSTRN* ind KO: 274; galactose: WT ind: 186, *SPAG5* ind KO: 214, *KNSTRN* ind KO: 202). Scatter dots represent cells of all three replicates and symbols differ for cells belonging to different replicates. Graph shows mean $\pm$ SD. (D, E) Representative electron micrographs of WT, *SPAG5* and *KNSTRN* ind-KO (D) or WT and *CLUH* KO (E) HeLa cells. Scale bar, 1000 nm.

Figure 6-figure supplement 1. Loss of SPAG5 and CLUH lead to hyperactivation of mTORC1 signaling.

(A, B) MSigDB Hallmark pathways of downregulated (E) or upregulated (F) proteins (with a cut-off of $p \leq 0.05$; $q \leq 0.15$) detected in proteomics analysis of *SPAG5* ind-KO cells (Fig 4A and Supplementary Table3) using the EnrichR webtool. (C) Western blots of WT and *SPAG5* ind-KO HeLa cells transfected with siRNA against CLUH or untargeted control siRNA. Cells were induced for four days with doxycycline, additionally downregulated for the last three days and grown for the last 8 h in basal or HBSS media without doxycycline. Pan-actin was used as loading control. (D) Quantification of experiments as shown in C (n=4 independent experiments). Antibody signal was normalized to pan-actin signal, and signal of phospho-protein was normalized to signal of the total protein. Bars show mean $\pm$ SEM and dots represent values of individual replicates. One-way ANOVA with post hoc Tukey's multiple comparison tests were performed with $P \leq 0.05$: *; $P \leq 0.01$: **; $P \leq 0.001$: ***.

Figure 6-figure supplement 2. Astrin and kinastrin depletion does not affect cellular metabolism under basal conditions.

(A-F) Targeted metabolomics of WT, *SPAG5* and *KNSTRN* ind-KO HeLa cells under basal conditions (A-E) or after 8h HBSS starvation (F) showing glycolytic intermediates and lactic acid (A), sedoheptulose-7-P (B), pyruvic acid and TCA cycle intermediates (C), nucleotide (D) and amino acid levels (E-F). Bars show mean $\pm$ SEM and dots represent values of individual replicates. One-way ANOVA with post hoc Tukey's multiple comparison tests were performed on log converted fold changes with $P \leq 0.05$: *; $P \leq 0.01$: **.

Figure 8- figure supplement 1. Model of CLUH/astrin-1 complex function in proliferating cells.

CLUH and astrin-1 form a complex and regulate each other reciprocally. On the one hand, CLUH is required for astrin synthesis and for protein stability. Additionally, CLUH promotes mitochondrial anaplerotic reactions and OXPHOS function by ensuring CLUH-target expression. This provides energy and building blocks to increase anabolic pathways like nucleotide synthesis, glycolysis, pentose phosphate pathway and polyamine synthesis required for growth in G1 and allowing cell cycle progression at the G1/S boundary. Astrin-1 on the other hand regulates CLUH localization, controls metaphase to anaphase progression in M phase and inhibits mTORC1.

SUPPLEMENTARY TABLES

Supplementary Table 1: Interactors of endogenous human CLUH in HeLa cells after SILAC labeling

Supplementary Table 2: Interactors of endogenous human CLUH in G2-enriched HeLa cells

Supplementary Table 3: Proteomics data of *SPAG5* and *KNSTRN* ind-KO HeLa cells

Supplementary Table 4: IC-TQ_Transitions compound list

SOURCE DATA

Figure 1-source data 1. Uncropped blots for Figure 1A

Figure 1-source data 2. Uncropped blots for Figure 1B

Figure 1-source data 3. Uncropped blots for Figure 1D

Figure 1-source data 4. Uncropped blots for Figure 1E

Figure 1-source data 5. Uncropped blots for Figure 1F

Figure 1-source data 6. Uncropped blots for Figure 1G

Figure 1-figure supplement 1-source data 1. Uncropped blots for Figure 1-figure supplement 1B

Figure 1-figure supplement 1-source data 2. Uncropped blots for Figure 1-figure supplement 1C

Figure 1-figure supplement 1-source data 3. Uncropped blots for Figure 1-figure supplement 1D

Figure 2-source data 1. Uncropped blots for Figure 2A

Figure 2-source data 2. Uncropped blots for Figure 2H

Figure 2-figure supplement 1-source data 1. Uncropped blots for Figure 2-figure supplement 1A

Figure 3-source data 1. Uncropped blots for Figure 3A

Figure 4-source data 1. Uncropped blots for Figure 4D

Figure 5-source data 1. Uncropped blots for Figure 5D

Figure 5-figure supplement 1-source data 1. Uncropped blots for Figure 5-figure supplement 1A

Figure 5-figure supplement 1-source data 2. Uncropped blots for Figure 5-figure supplement 1B

Figure 6-figure supplement 1-source data 1. Uncropped blots for Figure 6-figure supplement 1C

Figure 8-source data 1. Uncropped blots for Figure 8F